EP0851925A1 - Varianten des menschlichen wachstumshormons - Google Patents

Varianten des menschlichen wachstumshormons

Info

Publication number
EP0851925A1
EP0851925A1 EP96931597A EP96931597A EP0851925A1 EP 0851925 A1 EP0851925 A1 EP 0851925A1 EP 96931597 A EP96931597 A EP 96931597A EP 96931597 A EP96931597 A EP 96931597A EP 0851925 A1 EP0851925 A1 EP 0851925A1
Authority
EP
European Patent Office
Prior art keywords
hgh
variant
growth hormone
human growth
hormone variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96931597A
Other languages
English (en)
French (fr)
Other versions
EP0851925B1 (de
Inventor
Brian C. Cunningham
Henry B. Lowman
James A. Wells
Ross G. Clark
Kenneth Olson
Germaine G. Fuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0851925(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to DK05007536.5T priority Critical patent/DK1568772T3/da
Priority to EP05007536A priority patent/EP1568772B1/de
Priority to EP05007535A priority patent/EP1568771A3/de
Publication of EP0851925A1 publication Critical patent/EP0851925A1/de
Application granted granted Critical
Publication of EP0851925B1 publication Critical patent/EP0851925B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Definitions

  • This invention relates to certain growth hormone variants, and pegylated forms thereof, for use as agonists or antagonists of human growth hormone.
  • hGH Human growth hormone
  • hGH is a member of a family of homologous hormones that include placental lactogens, prolactins, and other genetic and species variants of growth hormone. Nichol et al . , Endocrine Reviews. 2: 169 (1986). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung et al . , Nature. 330: 537 [1987]) or prolactin (Boutin et al . , Cell. 53 : 69 [1988]) receptor.
  • the cloned gene for hGH has been expressed in a secreted form in E . coli (Chang et al . , Gene. 55: 189 [1987]) and its DNA and amino acid sequences have been reported. Goeddel et al . , Nature. 281: 544 (1979); Gray et al . , Gene. 39: 247 (1985) .
  • the three- dimensional folding pattern for porcine growth hormone (pGH) has been reported at moderate resolution and refinement. Abdel-Meguid et al . , Proc. Natl. Acad. Sci. USA. 84: 6434 (1987) .
  • the receptor and antibody epitopes of hGH have been identified by homolog- scanning mutagenesis and alanine-scanning mutagenesis as described in the priority application to this application and in Cunningham et al . , Science. 243 : 1330-1336 (1989) and Cunningham and Wells, Science, 244: 1081-1085 (1989) .
  • hGH-V Seeberg, DNA. 1: 239 (1982); U.S. Pat. Nos. 4,446,235, 4,670,393, and 4,665,180] and 20K hGH containing a deletion of residues 32-46 of hGH. Kostyo et al . , Biochem. Biophys. Acta. 925: 314 (1987); Lewis et al . J. Biol. Chem.. 253: 2679 (1978) .
  • hGH has an additional glutamine after position 68, a glutamic acid rather than glutamine at position 73, an aspartic acid rather than asparagine at position 106, and an asparagine rather than aspartic acid at position 108.
  • binding properties can be engineered by replacement of entire units of secondary structure including antigen binding loops (Jones et al . , Nature, 321: 522-525 [1986]) or DNA recognition helices. Wharton et al . , Nature. 316: 601-605 (1985).
  • hGH amino-terminal methionyl bovine growth hormone
  • hGH variants are also reported in WO 92/21029 published 26 November 1992, which discloses the 1:2 complex dimer between GH and two receptor molecules.
  • the variant is a monomeric polypeptide ligand which comprises in its native conformation four amphipathic alpha helices and which binds to its receptor through two sites in sequential order.
  • This variant comprises a mutation introduced into site 1 or site 2, provided that when the ligand is GH, at least two residues are mutated, one each in the N-terminal about 15 residues of the wild-type hormone and in helix C, or site 1 is mutated so as to increase the affinity of the ligand for its receptor at site 1.
  • the in vivo efficacy of hGH and hGH variants is determined, in part, by affinity for hGH receptor and by the rate of clearance from the circulation.
  • the in vivo half-life of certain other therapeutic proteins has been increased by conjugating the proteins with PEG, which is termed "pegylation.”
  • PEG is typically characterized as a non-immunogenic uncharged polymer with three water molecules per ethylene oxide monomer. PEG is believed to slow renal clearance by providing increased hydrodynamic volume in pegylated proteins. Maxfield et al . , Polymer.
  • hGH human growth hormone
  • H18D H21N, R167N, K168A, D171S, K172R, E174S, I179T.
  • human growth hormone variant including the following set of amino acid substitutions:
  • An hGH variant including one of these sets of amino acid substitutions acts as an hGH agonist in the absence of an additional modification that disrupts binding to the hGH receptor at Site 2.
  • an hGH variant including an amino acid substitution at G120 acts as an hGH antagonist.
  • the present invention provides hGH variants wherein a G120 amino acid substitution is combined with one of the sets of Site 1 amino acid substitutions.
  • an hGH variant includes the following set of amino acid substitutions:
  • an hGH variant includes the following set of amino acid substitutions: H18A, Q22A, F25A, D26A, Q29A, E65A, G120K, K168A, E174A (hereinafter the "B2024 variant”) .
  • hGH variants conjugated to one or more chemical groups that increase the molecular weight of the variant, as determined by mass spectrometry (hereinafter "actual molecular weight") , to at least about 40 kilodaltons.
  • an hGH variant is conjugated to one or more polyols, such as poly(ethylene glycol) (PEG). Also provided is a method of producing an hGH variant conjugated to PEG.
  • a further aspect of the invention is a method for inhibiting growth hormone action in a patient comprising administering to the patient an effective amount of an antagonist hGH variant of the invention.
  • Figures 1A and IB show the reaction (Fig. 1A) and kinetics (Fig. IB) for binding of human growth hormone (hGH) or (G120R)hGH to the (S237C)hGHbp coupled to the BIAcoreTM biosensor.
  • the (S237C)hGHbp was immobilized on the thiol-dextran matrix (Fig. 1A) at a level of 1220 RU's, which corresponds to 1.2 ng/mm 2 .
  • Fig. 1A thiol-dextran matrix
  • FIG. 2A and 2B show the reaction (Fig. 2A) and kinetics (Fig. 2B) for binding of hGH (open symbols) or (G120R)hGH (closed symbols) to the (s201C)hGHbp coupled on the BIAcoreTM biosensor.
  • the (S201C)hGHbp was immobilized at a level of 1480 RU's (1.48 ng/mm 2 ) on the biosensor. Binding conditions and profiles are analogous to those in Figs. 1A and IB.
  • Figure 3 shows the correlation between the change in the free energy of binding ( ⁇ G (mut . wl) ) calculated for alanine mutants of hGH relative to wild-type hGH when forming a 1:1 complex with the hGHbp from data obtained by RIA (y-axis) or BIAcoreTM biosensor (x-axis) . Values were taken from Table 2.
  • Figures 4A and 4B show the relative change in off- rate (Fig. 4A) or on-rate (Fig. 4B) for alanine mutants at contact residues. Data is taken from Table 2.
  • Figures 5A and 5B show the relationship between the change in binding affinity upon alanine substitution and the change in buried surface area (A 2 ) (Fig. 5A) or number of van der Waals contacts (Fig. 5B) for atoms in contact side-chains beyond the 0-carbon. Closed circles are for residues buried at the interface that make hydrogen bonds or salt bridges with the receptor at Site 1, and open circles are for residues that do not. Data are plotted from Table 2.
  • Figures 6A, 6B, and 6C show a comparison of receptor binding epitopes defined by alanine-scanning mutagenesis, x-ray crystal structure, or phage display, respectively.
  • Fig. 6A shows the hGH site-1 functional epitope. Residues involved in receptor binding, according to alanine-scanning mutagenesis, are shown on a cartoon model of hGH, derived from the hGH(hGHbp) 2 crystal structure. de Vos et al . , supra .
  • alanine substitutions or Gin substitution in the case of K41
  • BIAcoreTM kinetics measurements except for sites M14, H21, F54, E56, 158, S62, N63, and Y164.
  • BIAcoreTM data were either not available or indicated negligible effect on binding, and so the effect shown is based on RIA data.
  • the four white spheres of increasing size denote alanine substitutions that reduced binding energy by +0.5 to 1.0 kcal/mol, +1.0 to 1.5 kcal/mol, +1.5 to 2.0 kcal/mol, or +2.0 to 2.5 kcal/mol, respectively.
  • Fig. 6B is the hGH site-1 structural epitope.
  • the four white spheres of increasing size represent a change in solvent-accessible area of -20 to 0 A 2 , 0 to 20 A 2 , 20 to 40 A 2 , or 40 to 60 A 2 , respectively, at each residue upon alanine substitution, as calculated from the hGH(hGHbp) 2 X-ray crystal structure.
  • Fig. 6C denotes the conservation of hGH residues in randomized phagemid libraries. Residues that were randomized, four positions at a time, in phage- displayed hGH libraries are shown: helix-l [F10, M14, H18, H21]; minihelix-1 [K41, Y42, L45, Q46]; Loop-A [F54, E56, 158, R64]; helix-4A [K172, E174, F176, R178]; helix-4B [R167, D171, T175, 1179].
  • the fraction of wild-type hGH residues found at each position after sorting for hGHbp binding is indicated by the size of black spheres: The smallest black sphere is 0-10% conserved, the next larger is 10-25% conserved, the next larger is 25-50% conserved, and the largest is >50% conserved.
  • Figure 7 shows the strategy for combining phage- derived mutations that enhance receptor binding affinity. The best selectants are shown with the fold increase in affinity over wild-type. The number of mutations from wild-type found in each of these variants is also shown (e . g . , 4 muts.). Libraries randomized at four codons each in helix-1, helix-4, minihelix-1, or the loop connecting helices 1 and 2, were sorted separately. Two mutations (E174S/F176Y) identified in Helix-4a were used as background for additional randomization and selection at other helix-4 sites (Helix-4b; Lowman et al . , supra) .
  • FIGS. 8A, 8B, and 8C depict the relationship among the hGH structural epitope, phage-derived epitope, and evolutionary variants, respectively.
  • the natural logarithm of the frequency with which the wild- type hGH residues appeared in hGH-phagemid pools (Lowman et al . , supra ) sorted for receptor binding is shown on the x-axis. Data from the Combinatorial libraries were not included. The log scale was chosen for comparison with buried surface areas. Residues M14, H18, K41, Q46, R167, and E174 do not appear on this graph, because no wild-type residues were found among any of the selected libraries.
  • Fig. 8A depicts a comparison with x-ray structure of hGH-(hGHbp) 2 .
  • the side-chain area of hGH residues buried by receptor-1 binding (solvent accessible area of: [free hGH] - [hGH-hGHbp complex] is plotted.
  • Fig. 8B depicts the results of phage display and alanine-scanning mutagenesis.
  • the functional effect of Ala substitutions in hGH is plotted as In [K d (Ala mutant) /K d (hGH) ] . Binding data were taken from BIAcoreTM biosensor measurements, except where kinetics data were not available.
  • Figure 9 discloses the additivity of phage-derived mutations.
  • the change ( ⁇ G) in free energy of binding versus that of wild-type hGH was compared with the sum of ⁇ G for component mutations.
  • the points shown correspond to the combinations of (1) variant BD vs. [B plus D] ; (2) variant 852b vs. [minihelix-l plus loop- A] ; (3) variant BF vs. [B plus F] ; and (4) variant 852d vs. [BD plus 852b].
  • Error bars were estimated from standard deviations using a propagation of errors calculation. Bevington, Data Reduction and Error
  • Figure 10 shows a plasmid map for an exemplary vector used to express an antagonist hGH variant of the present invention (the B2036 variant) , as described in Example V.
  • Figure 11 shows the effect of daily subcutaneous injections (0.25 mg/kg) of various antagonist hGH variants of the present invention on insulin-like growth factor-I (IGF-I) levels in Rhesus monkeys. Both pegylated and non-pegylated forms of the variants were tested. See Example XIII.
  • IGF-I insulin-like growth factor-I
  • Figure 12 shows the single-dose pharmacodynamics of a pegylated antagonist hGH variant (B2036) preparation injected intravenously or subcutaneously into Rhesus monkeys. Antagonist effect was measured as percent reduction in IGF-I level. See Example XIV.
  • the DNA and amino acid sequences of human growth hormone (hGH) have been reported. Goeddel et al . , supra; Gray et al . , supra .
  • the present invention describes novel hGH variants produced using either the alanine-scanning methodology or phagemid selection methods.
  • the hGH variants of the present invention can be expressed in any recombinant system that is capable of expressing wild-type or met hGH.
  • Variant hGH sequence notation defines the actual amino acid substitutions in the hGH variants of the present invention.
  • substitutions are indicated by a letter representing the wild-type residue (in single-letter code), a number indicating the amino acid position in the wild-type sequence, and a second letter indicating the substituted amino acid residue.
  • R64K indicates a mutation in which Arg 64 is converted to Lys.
  • Multiple mutants are indicated by a series of single mutants separated by commas.
  • the invention herein utilizes a systematic analysis of hGH to determine one or more active sites in the polypeptide that are involved in the interaction of the polypeptide with its receptor. Such analysis is conveniently performed using recombinant DNA technology.
  • the DNA sequence encoding hGH is cloned and manipulated so that it can be expressed in a convenient host.
  • DNA encoding hGH can be obtained from a genomic library, from cDNA derived from mRNA in cells expressing the hGH, or by synthetically constructing the DNA sequence.
  • Maniatis et al . Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, N.Y. (1982) .
  • the wild-type hGH DNA is then inserted into an appropriate plasmid or vector that i ⁇ used to transform a host cell.
  • Prokaryotes are preferred for cloning and expressing DNA sequences to produce the hGH variants.
  • E . coli K12 strain 294 ATCC No. 31446
  • E . coli B E . coli X1776
  • E . coli c600 and c600hfl ATCC No. 31510
  • E . coli W3110 F " , 7', prototrophic, ATCC No.
  • the hGH When expressed intracellularly in prokaryotes, the hGH typically contains an N-terminal methionine or a for yl methionine and is not glycosylated. When expressed extracellularly into the medium or the periplasm, the hGH does not contain an N-terminal methionine.
  • eukaryotic organisms such as yeast cultures, or cells derived from multicellular organisms
  • any such cell culture is workable.
  • interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a repeatable procedure.
  • Tissue Culture Academic Press, Kruse and Patterson, editors (1973) .
  • useful host cell lines are VERO and HeLa, Chinese hamster ovary (CHO), W138, BHK, COS-7, and MDCK cell lines.
  • Plasmid vectors containing replication and control sequences that are derived from species compatible with the host cell are used in connection with these hosts.
  • the vector ordinarily carries a replication site, as well as sequences that encode proteins that are capable of providing phenotypic selection in transformed cells.
  • E . coli can be transformed using pBR322, a plasmid derived from an E . coli species. Mandel et al . , J. Mol. Biol.. 53: 154 (1970) .
  • Plasmid pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for selection.
  • One preferred vector is pB0475, described in Example 1 of a priority application to this application (U.S.S.N.
  • Expression vector refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host.
  • control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation.
  • the vector can be a plasmid, a phage particle, or simply a potential genomic insert.
  • the vector can replicate and function independently of the host genome, or can, in some instances, integrate into the genome itself.
  • plasmid and “vector” are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present.
  • the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.
  • operably linked when describing the relationship between two DNA or polypeptide regions simply means that they are functionally related to each other.
  • a presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein, most probably involving cleavage of the signal sequence.
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence;
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
  • site-specific mutagenesis (Carter et al . , Nucl. Acids. Res.. 13 : 4331 [1986]; Zoller et al . , Nucl. Acids Res.. 10: 6487 [1987]) , cassette mutagenesis (Wells et al . , Gene. 34. 315 [1985]), restriction selection mutagenesis (Wells et al . , Philos. Trans. R. Soc. London SerA.
  • the different GH variants are produced, they are contacted with the receptor and the interaction, if any, between the receptor and each variant is determined. These activities are compared to the activity of the wild-type hGH with the same receptor to determine which of the amino acid residues in the active domain are involved in the interaction with the receptor.
  • the scanning amino acid used in such an analysis can be any different amino acid from that substituted, i.e., any of the 19 other naturally occurring amino acids.
  • the target receptor can be isolated from natural sources or prepared by recombinant methods by procedures known in the art. By way of illustration, the receptor can be prepared by the technique described by McFarland et al . , Science. 245: 494-499 (1989) .
  • the interaction between the receptor and parent and variant can be measured by any convenient in vitro or in vivo assay.
  • in vitro assays can be used to determine any detectable interaction between a receptor and hGH. Such detection can include the measurement of colorimetric changes, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis, and/or gel exclusion methods, etc.
  • In vivo assays include, but are not limited to, assays to detect physiological effects, e.g., weight gain or change in electrolyte balance. Generally, any in vivo assay can be used so long as a variable parameter exists so as to detect a change in the interaction between the receptor and the hGH of interest.
  • K d dissociation constant of the complex formed between the hGH variant and receptor as compared to the K d for the wild-type hGH.
  • K d dissociation constant
  • a two-fold increase or decrease in K d per analogous residue substituted by the substitution indicates that the substituted residue(s) is active in the interaction of the wild-type hGH with the target.
  • the amino acid residues immediately adjacent thereto should be scanned.
  • Three residue-substituted polypeptides can be made.
  • the two others contain the scanning amino acid at position N+l and N-l. If each substituted hGH causes a greater than about two-fold effect on K d for the receptor, the scanning amino acid is substituted at position N+2 and N-2. This is repeated until at least one, and preferably four, residues are identified in each direction which have less than about a two-fold effect on K d or either of the ends of the wild-type hGH are reached. In this manner, one or more amino acids along a continuous amino acid sequence which are involved in the interaction with the particular receptor can be identified.
  • the active amino acid residue identified by amino acid scan is typically one that contacts the receptor target directly.
  • active amino acids can also indirectly contact the target through salt bridges formed with other residues or small molecules such as H 2 0 or ionic species such as Na + , Ca +2 , Mg +2 , or Zn +2 .
  • the substitution of a scanning amino acid at one or more residues results in a residue-substituted polypeptide which is not expressed at levels which allow for the isolation of quantities sufficient to carry out analysis of its activity with the receptor.
  • a different scanning amino acid preferably an isosteric amino acid, can be used.
  • amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is the preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions. Creighton, The Proteins (W.H. Freeman &
  • an isosteric amino acid can be used.
  • the following amino acids in decreasing order of preference can be used: Ser, Asn, and Leu.
  • isosteric amino acids can be substituted. Such isosteric substitutions need not occur in all instances and can be performed before any active amino acid is identified. Such isosteric amino acid substitution is performed to minimize the potential disruptive effects on conformation that some substitutions can cause. Isosteric amino acids are shown in the table below: Isosteric
  • the method herein can be used to detect active amino acid residues within different active domains. Once this identification is made, various modifications to the wild-type hGH can be made to modify the interaction between the parent hGH and one or more of the targets.
  • hGH for hGH in particular, exemplary of the present invention is a preferred embodiment wherein the active domains and active residues which determine its activity with its somatogenic receptor (hGHbp) are identified.
  • hGH variants including amino-acid-re ⁇ idue substituted hGH variants, have been made or identified which have different binding interactions with hGHbp a ⁇ compared to naturally occurring hGH. Some can have a higher affinity for hGHbp and enhanced potency for somatogenesis in rats. Others have a decreased activity with hGHbp.
  • Such hGH variants are useful as hGH agonists or antagonists and can have a higher potency for stimulating other receptors for hGH, if such variants are freed from substantial interaction with hGHbp. Further, such variants are useful in immunoassays for hGH as an hGH standard or tracer. Some variants can be identified which have a significant decrease in reactivity with human and mouse serum containing anti-hGH polyclonal antibodies. Others have the same binding affinity for hGHbp as hGH but increased potency to stimulate growth.
  • the variants can be analyzed by phagemid display.
  • This method involves (a) constructing a replicable expression vector comprising a first gene encoding the hGH, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second gene ⁇ are heterologous, and a transcription regulatory element operably linked to the first and ⁇ econd gene ⁇ , thereby forming a gene fusion encoding a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids; (c) transforming suitable host cells with the plasmids; (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the
  • the plasmid is under tight control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about 1%. Also, preferably, the amount of phagemid particles displaying more than one copy of the fusion protein is less than 10% of the amount of phagemid particles displaying a single copy of the fusion protein. Most preferably, the amount is less than 20%.
  • the expression vector further contains a secretory signal sequence fused to the DNA encoding each subunit of the polypeptide and the transcription regulatory element is a promoter system.
  • Preferred promoter systems are selected from lac Z, ⁇ PL , tac. T7 polymerase, tryptophan, and alkaline phosphatase promoters and combinations thereof.
  • the method employs a helper phage selected from M13K07, M13R408, M13-VCS, and Phi X 174.
  • the preferred helper phage is M13K07, and the preferred coat protein is the M13 Phage gene III coat protein.
  • the preferred host is E . coli , and protease-deficient strains of E . coli .
  • Novel hGH variants selected by the method of the present invention have been detected.
  • Phagemid expression vectors were constructed that contain a suppressible termination codon functionally located between the nucleic acids encoding the polypeptide and the phage coat protein.
  • repeated cycles of hGH selection are used to select for higher and higher affinity binding by the phagemid selection of multiple amino acid changes which are selected by multiple selection cycles.
  • additional rounds of phagemid selection in other regions or amino acids of the ligand polypeptide are conducted.
  • the cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved.
  • phagemid selection of hGH was conducted in cycles.
  • amino acids 172, 174, 176, and 178 can be mutated and phagemid selected.
  • amino acids 167, 171, 175, and 179 can be phagemid selected.
  • hGH amino acids 10, 14, 18, and 21 can be phagemid selected.
  • Optimum amino acid changes from a previous cycle can be incorporated into the polypeptide before the next cycle of selection. For example, hGH amino acids substitutions 174 (serine) and 176
  • the amino acid residues that form the binding domain of the hGH are not sequentially linked and can reside on different subunits of the polypeptide. That is, the binding domain tracks with the particular secondary structure at the binding site and not the primary structure.
  • mutations are introduced into codons encoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they have the potential to interact with the receptor.
  • the location of residues in hGH that strongly modulate its binding to the hGH receptor (Cunningham et al . , Science. 1990, supra) are known.
  • telomeres 172, 174, 176, and 178 on helix-4 residues 172, 174, 176, and 178 on helix-4, as well as residue 64 located in a "non-ordered" secondary structure.
  • a suitable vector preferably a plasmid
  • plasmid vectors are the preferred vectors for use herein, as they can be constructed with relative ease, and can be readily amplified.
  • Plasmid vectors generally contain a variety of components, including promoters, signal sequences, phenotypic selection genes, origin of replication sites, and other necessary components as are known to those of ordinary skill in the art. Promoters most commonly used in prokaryotic vectors include the lac Z promoter system, the alkaline phosphatase pho A promoter, the bacteriophage ⁇ PL promoter (a temperature-sensitive promoter) , the tac promoter (a hybrid trp-lac promoter that is regulated by the lac repressor) , the tryptophan promoter, and the bacteriophage T7 promoter. For general descriptions of promoters, see section 17 of Sambrook et al . , supra .
  • promoters for practicing this invention for phagemid display are those that can be tightly regulated such that expression of the fusion gene can be controlled. It is believed that the problem that went unrecognized in the prior art was that display of multiple copies of the fusion protein on the surface of the phagemid particle lead to multipoint attachment of the phagemid with the target.
  • This effect is believed to result in selection of false "high affinity" polypeptides when multiple copies of the fusion protein are displayed on the phagemid particle in close proximity to one another so that the target was "chelated.”
  • the effective or apparent K d can be as high as the product of the individual K d s for each copy of the displayed fusion protein. It has been discovered that by tightly regulating expression of the fusion protein so that no more than a minor amount, i.e., fewer than about 1%, of the phagemid particles contain multiple copies of the fusion protein, the "chelate effect" is overcome, allowing proper selection of high-affinity polypeptides.
  • culturing conditions of the host are adjusted to maximize the number of phagemid particles containing a single copy of the fusion protein and minimize the number of phagemid particles containing multiple copies of the fusion protein.
  • Preferred promoters used to practice this invention are the lac Z promoter and the pho A promoter.
  • the lac Z promoter is regulated by the lac repressor protein lac i, and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein.
  • the phagemid containing the lac Z promoter is grown in a cell strain that contains a copy of the lac i repressor gene, a repressor for the lac Z promoter.
  • Exemplary cell strains containing the lac i gene include JM 101 and XLl-blue.
  • the host cell can be cotransfected with a plasmid containing both the repressor lac i and the lac Z promoter.
  • phagemid particles containing the lac Z promoter are grown in cell strains containing the lac i gene and the cell strains are cotransfected with a plasmid containing both the lac Z and lac i genes.
  • an inducer such as isopropylthiogalactoside (IPTG) .
  • thi ⁇ step is omitted to (a) minimize the expression of the gene III fusion protein, thereby minimizing the copy number (i.e., the number of gene III fusions per phagemid number) and to (b) prevent poor or improper packaging of the phagemid caused by inducers such as IPTG even at low concentrations.
  • the number of fusion proteins per phagemid particle is about 0.1 (number of bulk fusion proteins/number of phagemid particles) .
  • the most preferred promoter used to practice this invention is pho A. This promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down- regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by growing cells in a phosphate-enriched medium such as 2 T or LB, thereby controlling the expression of the gene III fusion.
  • One other useful component of vectors used to practice this invention is a signal sequence.
  • This sequence is typically located immediately 5' to the gene encoding the fusion protein, and is thus transcribed at the amino terminus of the fusion protein. However, in certain cases, the signal sequence has been demonstrated to be located at positions other than 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attached across the inner membrane of the bacterial cell.
  • the DNA encoding the signal sequence can be obtained as a restriction endonuclease fragment from any gene encoding a protein that has a signal sequence. Suitable prokaryotic signal sequences can be obtained from genes encoding, for example, lamB or ompF (Wong et al . , Gene.
  • a preferred prokaryotic signal sequence for practicing this invention is the E . coli heat-stable enterotoxin II (STII) signal sequence as described by Chang et al . , supra .
  • STII enterotoxin II
  • phenotypic selection genes are those encoding proteins that confer antibiotic resistance upon the host cell.
  • ampicillin resistance gene (amp) and the tetracycline resistance gene (tet) are readily employed for this purpose.
  • Construction of suitable vectors comprising the aforementioned components as well as the gene encoding the hGH (gene 1) are prepared using standard recombinant DNA procedures as described in Sambrook et al * , supra . Isolated DNA fragments to be combined to form the vector are cleaved, tailored, and ligated together in a specific order and orientation to generate the desired vector.
  • the DNA is cleaved using the appropriate restriction enzyme or enzymes in a suitable buffer.
  • a suitable buffer In general, about 0.2-1 ⁇ g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 ⁇ l of buffer solution.
  • Appropriate buffers, DNA concentrations, and incubation times and temperatures are specified by the manufacturers of the restriction enzymes. Generally, incubation times of about one or two hours at 37°C are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
  • the ends of the DNA fragments must be compatible with each other. In some cases, the ends are directly compatible after endonuclease digestion. However, it can be necessary to first convert the sticky ends commonly produced by endonuclease digestion to blunt ends to make them compatible for ligation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15°C with 10 units of the Klenow fragment of DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation.
  • the cleaved DNA fragments can be size-separated and selected using DNA gel electrophoresis.
  • the DNA can be electrophoresed through either an agarose or a polyacrylamide matrix. The selection of the matrix depends on the size of the DNA fragments to be separated.
  • the DNA is extracted form the matrix by electroelution, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et al . , supra .
  • the DNA fragments that are to be ligated together are put in solution in about equimolar amounts.
  • the solution also contains ATP, ligase buffer, and a ligase such as T4 DNA ligase at about 10 units per 0.5 ⁇ g of DNA.
  • the vector is at first linearized by cutting with the appropriate restriction endonuclease(s) .
  • the linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligation of the vector during the ligation step.
  • Suitable prokaryotic host cells include E . coli strain JMlOl, E . coli K12 strain 294 (ATCC number 31,446), E . coli strain W3110 (ATCC number 27,325), E . coli X1776 (ATCC number 31,537), E . coli XL-lBlue (Stratagene) , and E . coli B; however, many other strains of E. coli , such as HB101, NM522, NM538, and
  • bacilli such as Bacillus subtilis
  • enterobacteriaceae such as Salmonella typhimurium or Serratia marce ⁇ cens
  • various Pseudomonas species can all be used as hosts.
  • Transformation of prokaryotic cells is readily accomplished using the calcium chloride method as described in section 1.82 of Sambrook et al . , supra .
  • electroporation (Neumann et al . , EMBO J.. 1 : 841 [1982]) can be used to transform these cells.
  • the transformed cells are selected by growth on an antibiotic, commonly tet or amp, to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector.
  • antibiotic commonly tet or amp
  • these cells are grown in culture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Plasmid DNA can be isolated using methods known in the art.
  • DNA sequencing is generally performed by either the method of Messing et al . , Nucleic Acids Res.. 9_: 309 (1981), the method of Maxam et al . , Meth. Enzymol.. 65: 499 (1980), or the method of Sanger et al . , Proc. Natl. Acad. Sci. USA. 74: 5463-5467 (1977).
  • the phagemid-display method herein contemplates fusing the gene encoding the hGH (gene 1) to a second gene (gene 2) such that a fusion protein is generated during transcription.
  • Gene 2 is typically a coat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusion of genes 1 and 2 can be accomplished by inserting gene 2 into a particular site on a plasmid that contains gene 1, or by inserting gene 1 into a particular site on a plasmid that contains gene 2.
  • Insertion of a gene into a plasmid requires that the plasmid be cut at the precise location that the gene is to be inserted. Thus, there must be a restriction endonuclease site at this location (preferably a unique site such that the plasmid is only cut at a single location during restriction endonuclease digestion) .
  • the plasmid is digested, phosphatased, and purified as described above.
  • the gene is then inserted into this linearized plasmid by ligating the two DNAs together. Ligation can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted.
  • the DNAs can be ligated together directly with a ligase such as bacteriophage T4 DNA ligase by incubating the mixture at 16°C for 1-4 hours in the presence of ATP and ligase buffer as described in section 1.68 of Sambrook et al . , supra .
  • a ligase such as bacteriophage T4 DNA ligase
  • ends are not compatible, they must first be made blunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonucleotide triphosphates to fill in overhanging single-stranded ends of the digested DNA.
  • the ends can be blunted using a nuclease such as nuclease SI or mung-bean nuclease, both of which function by cutting back the overhanging single strands of DNA.
  • the DNA is then religated using a ligase as described above.
  • oligonucleotide linkers can be used. The linkers serve as a bridge to connect the plasmid to the gene to be inserted. These linkers can be made synthetically as double-stranded or single-stranded DNA using standard methods.
  • the linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to this gene using ligation methods described above.
  • the other end of the linkers is designed to be compatible with the plasmid for ligation.
  • care must be taken not to destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid.
  • it can be necessary to design the linkers such that they code for part of an amino acid, or such that they code for one or more amino acids.
  • DNA encoding a termination codon can be inserted, such termination codons being UAG (amber) , UAA (ocher) , and UGA (opel) .
  • the termination codon expressed in a wild-type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached.
  • growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein.
  • Such suppressor host cells contain a tRNA modified to insert an amino acid in the termination codon position of the mRNA, thereby resulting in production of detectable amounts of the fusion protein.
  • Such suppressor host cells are well known and described, such as E. coli suppressor strain. Bullock et al . , BioTechnigues. 5 . : 376-379 (1987) . Any acceptable method can be used to place such a termination codon into the mRNA encoding the fusion polypeptide.
  • the suppressible codon can be inserted between the hGH gene and a second gene encoding at least a portion of a phage coat protein.
  • the suppressible termination codon can be inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acid in the phage coat protein.
  • the polypeptide is synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell.
  • the hGH gene can be altered at one or more selected codons.
  • An alteration is defined as a substitution, deletion, or insertion of one or more codons in the gene encoding the hGH that results in a change in the amino acid sequence of the hGH as compared with the unaltered or wild-type sequence of the hGH.
  • the alterations are by substitution of at least one amino acid with any other amino acid in one or more regions of the molecule.
  • the alterations can be produced by a variety of methods known in the art. These methods include, but are not limited to, oligonucleotide-mediated mutagenesis and cassette mutagenesis.
  • Oligonucleotide-mediated mutagenesis is the preferred method for preparing substitution, deletion, or insertion variants of hGH.
  • the technique is well known in the art as described by Zoller et al . , supra .
  • the hGH gene is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or wild- type DNA sequence for hGH.
  • a DNA polymerase is used to synthesize an entire second complementary strand of the template, and thus incorporates the oligonucleotide primer and codes for the selected alteration in the hGH gene.
  • oligonucleotides of at least 25 nucleotides in length are used. Although smaller oligonucleotides can be employed, an optimal oligonucleotide has 12 to 15 nucleotides that are complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide hybridizes properly to the single-stranded DNA template molecule.
  • the oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al . , Proc. Natl. Acad. Sci. USA. 75: 5765 (1978) .
  • the DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mpl8 and M13mpl9 vectors are suitable) , or those vectors that contain a single-stranded phage origin of replication a ⁇ described by Vieira and Messing, Meth. Enzvmol.. 153: 3-11 (1987) .
  • the DNA that is to be mutated must be inserted into one of these vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21 - 4.41 of Sambrook et al . , supra .
  • the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions.
  • a DNA polymerizing enzyme usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis.
  • a heteroduplex molecule i ⁇ thus formed such that one strand of DNA encodes the mutated form of the hGH gene, and the other strand (the original template) encodes the wild-type, unaltered sequence of the hGH gene.
  • This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as E . coli JMlOl.
  • the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.
  • the method described immediately above can be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s).
  • the modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above.
  • dATP deoxyriboadenosine
  • dGTP deoxyriboguanosine
  • dTTP deoxyribothymidine
  • this new strand of DNA contains dCTP-(AS) instead of dCTP, which serve ⁇ to protect it from restriction endonuclease dige ⁇ tion.
  • the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded.
  • a complete double- stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as E . coli JMlOl, a ⁇ de ⁇ cribed above.
  • Mutants with more than one amino acid to be substituted can be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they can be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If however, the amino acids are located some distance from each other (separated by more than about ten amino acids) , it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods can be employed.
  • a separate oligonucleotide is generated for each amino acid to be substituted.
  • the oligonucleotides are then annealed to the single- stranded template DNA simultaneously, and the second strand of DNA that is synthesize ⁇ form the template encodes all of the desired amino acid substitutions.
  • the alternative method involves two or more rounds of mutagenesis to produce the desired mutant.
  • the first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution( ⁇ ) is annealed to this template, and the heteroduplex DNA molecule is then generated.
  • the second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template.
  • this template already contains one or more mutations.
  • the oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and ⁇ econd round ⁇ of mutagenesis.
  • This resultant DNA can be used as a template in a third round of mutagenesis, and so on.
  • Cassette mutagenesis is also a preferred method for preparing substitution, deletion, and insertion variants of hGH DNA.
  • the method is based on that described by Wells et al . , Gene, supra .
  • the starting material is the plasmid (or other vector) comprising the hGH gene to be mutated.
  • the codon(s) in the hGH gene to be mutated are identified.
  • there is a unique restriction endonuclease site on each side of the identified mutation site(s) however, this is not a requirement.
  • restriction site If no such restriction site ⁇ exi ⁇ t, they can be generated u ⁇ ing the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the hGH gene. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it.
  • a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette.
  • This cas ⁇ ette i ⁇ designed to have 3' and 5* ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid.
  • This plasmid now contains the mutated DNA sequence of hGH.
  • the purified receptor is attached to a suitable matrix such as a ⁇ agaro ⁇ e bead ⁇ , acrylamide beads, glass beads, cellulose, various acrylic copolymers, hydroxyalkyl methacrylate gels, polyacrylic acid, polymethacrylic copolymers, nylon, neutral and ionic carriers, and the like. Attachment of the receptor to the matrix can be accomplished by methods described in Meth. Enzymol.. 44 : (1976), or by other means known in the art.
  • the immobilized target is contacted with the library of phagemid particles under condition ⁇ ⁇ uitable for binding of at least a portion of the phagemid particles with the immobilized target.
  • the conditions including pH, ionic strength, temperature, and the like mimic physiological conditions.
  • Bound phagemid particles (“binders") having high affinity for the immobilized receptor are separated from those having a low affinity (and thus do not bind to the target) by washing. Binders can be dissociated from the immobilized target by a variety of methods. These methods include competitive dissociation using the wild-type ligand, altering pH and/or ionic strength, and methods known in the art.
  • Suitable host cells are infected with the binders and helper phage, and the host cells are cultured under conditions suitable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times until binders having the desired affinity for the target molecule are selected.
  • the library of phagemid particles can be sequentially contacted with more than one immobilized receptor to improve selectivity for a particular receptor.
  • hGH has more than one natural receptor: the GH receptor and the prolactin receptor. It may be desirable to improve the selectivity of hGH for the GH receptor over the prolactin receptor. This can be achieved by first contacting the library of phagemid particles with immobilized GH receptor, allowing binding to occur in the presence of a very high concentration of prolactin receptor in solution, and selecting for binders. In this case, an hGH mutant having a lower affinity for the prolactin receptor would have therapeutic utility even if the affinity for the GH receptor were somewhat lower than that of wild-type hGH. Production of hGH Variants
  • hGH variants of the present invention can be conveniently produced by standard recombinant techniques. More specifically, an hGH variant can be expressed using a vector-host cell system, such as described above in the discussion of alanine scanning.
  • a phagemid of the present invention is used to produce an hGH variant free of the phage protein.
  • pS0643 and derivatives can simply be grown in a non-suppressor strain such as 16C9.
  • the amber codon (TAG) leads to termination of translation, which yields free hormone.
  • the hGH variant is secreted from the ho ⁇ t cell and can be isolated from the culture medium as described below.
  • Host cells containing an hGH variant expres ⁇ ion vector are cultured under conditions suitable for cell growth and for expression of the hGH variant.
  • the culture medium contains appropriate nutrients and growth factors for the host cell employed.
  • the nutrients and growth factors required for growth of a selected host cell are, in many instances, well known or can be readily determined empirically by those skilled in the art. Suitable culture conditions for mammalian host cells, for instance, are described in Mammalian Cell Culture
  • the culture conditions should allow transcription, tran ⁇ lation, and protein tran ⁇ port between cellular compartment ⁇ .
  • Factor ⁇ that affect these processes are well-known and include, for example, DNA/RNA copy number; factors that stabilize RNA; nutrients, supplements, and transcriptional inducers or repressors present in the culture medium; temperature, pH, and osmolality of the culture; and cell den ⁇ ity.
  • the adjustment of these factors to promote expression in a particular vector-host cell system is within the level of skill in the art.
  • the cell culture procedure employed in the production of an hGH variant of the present invention can be any of a number of well-known procedures for large- or small-scale production of proteins.
  • hGH variant can be produced, for instance, in a batch, fed-batch, or continuous mode process.
  • the hGH variant is recovered from the culture medium or the periplasm. Conveniently, the variant is ⁇ ecreted into the peripla ⁇ mic space as a fully processed protein (i.e., lacking the secretion signal sequence) . However, the hGH variant can also be expressed intracellularly and recovered from cell lysates.
  • the hGH variant can be purified from culture medium or a cell lysate by any method capable of separating the variant from component ⁇ of the host cell or culture medium. Typically the hGH variant is separated from host cell and/or culture medium components that would interfere with pegylation, if desired, or with diagnostic or therapeutic use of the hGH variant.
  • the culture medium or cell lysate is usually centrifuged or filtered to remove cellular debris.
  • the supernatant is then typically concentrated or diluted to a desired volume or diafiltered into a suitable buffer to condition the preparation for further purification.
  • Further purification of the hGH variant typically includes separating deamidated and clipped forms of the hGH variant from the intact form.
  • the intact hGH variant can be separated from the des-phe-hGH variant, which lacks the N-terminal phenylalanine.
  • the hGH variant is purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, using a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing condition ⁇ u ⁇ ing Cooma ⁇ ie blue stain.
  • any of the following exemplary procedures can be employed for purification of an hGH variant: affinity chromatography; anion- or cation-exchange chromatography (using, e.g., DEAE SEPHAROSE); chromatography on silica; reverse phase HPLC; gel filtration (using, e.g., SEPHADEX G-75) ; hydrophobic interaction chromatography; metal-chelate chromatography; ultrafiltration/diafiltration; ethanol precipitation; ammonium sulfate precipitation; chromatofocusing; and displacement chromatography.
  • Exemplary protocols for purification of hGH variants (B2036 and B2024) , using a combination of anion exchange chromatography and hydrophobic interaction chromatography, are set forth in Examples V and VI.
  • the present invention provides hGH variants covalently attached (hereinafter "conjugated") to one or more chemical groups. Such conjugation produces an hGH variant conjugate having a greater actual molecular weight than the unmodified hGH variant.
  • the term "actual molecular weight” refers to the molecular weight, as measured by mass spectrometry (e.g., matrix-assisted laser desorption ionization mas ⁇ spectrometry) .
  • the actual molecular weight of the hGH variant conjugate is usually at least about 30 kD; preferably, in the range of about 35 kD to about 55 kD; and more preferably, in the range of about 40 kD to about 50 kD. Generally, the actual molecular weight of the hGH variant conjugate does not exceed 100 kD.
  • Chemical groups suitable for use in an hGH variant conjugate of the present invention are preferably not significantly toxic or immunogenic, i.e., any toxicity or immunogenicity observed with an hGH variant conjugate is not significantly (i.e., less than 50%) greater than any toxicity or immunogenicity observed with the corresponding unmodified hGH variant.
  • a chemical group is selected that reduces toxicity and/or immunogenicity associated with the unmodified hGH variant.
  • the chemical group is conveniently selected to produce an hGH variant conjugate that can be stored and used under conditions suitable for storage and use of the unmodified hGH variant.
  • Exemplary chemical groups include carbohydrates, such as, for example, tho ⁇ e carbohydrates that occur naturally on glycoproteins, and non-proteinaceou ⁇ polymer ⁇ , ⁇ uch as polyols.
  • a polyol for example, can be conjugated to an hGH variant molecule at one or more amino acid residues, including lysine residue ⁇ , as disclosed in WO 93/00109, supra .
  • the polyol employed can be any , water-soluble poly(alkylene oxide) polymer and can have a linear or branched chain. Suitable polyols include those substituted at one or more hydroxyl position ⁇ with a chemical group, such as an alkyl group having between one and four carbons.
  • the polyol is a poly(alkylene glycol) , ⁇ uch as poly(ethylene glycol) (PEG) , and thus, for ease of description, the remainder of the discussion relates to an exemplary embodiment wherein the polyol employed is PEG and the process of conjugating the polyol to an hGH variant is termed "pegylation.”
  • PEG poly(ethylene glycol)
  • pegylation the process of conjugating the polyol to an hGH variant
  • other polyols such as, for example, poly(propylene glycol) and polyethylene-polypropylene glycol copolymers, can be employed using the techniques for conjugation described herein for PEG.
  • the average molecular weight of the PEG can range from about 500 to about 30,000 daltons (D) ; preferably, from about 1,000 to about 25,000 D; and more preferably, from about 4,000 to about 20,000 D.
  • pegylation is carried out with PEG having an average molecular weight of about 5,000 D (hereinafter "PEG(5000) ") .
  • PEG(5000) the reaction conditions are adjusted to maximize production of hGH variant molecules conjugated to between about four and about ⁇ ix molecules of PEG(5000) .
  • pegylation is carried out with PEG having an average molecular weight of about 20,000 D under conditions adjusted to maximize production of hGH molecules conjugated to one molecule of PEG(20,000). See Example VIII.
  • a branched-chain PEG having two chains of about 10,000 D each is employed. See Example IX.
  • PEG preparations that are commercially available, and suitable for use in the present invention, are nonhomogeneous preparations that are sold according to average molecular weight.
  • PEG(5000) preparations typically contain molecules that vary slightly in molecular weight, usually ⁇ 500 D.
  • a variety of methods for pegylating proteins have been described. See, e.g., U.S. Patent No. 4,179,337 (issued to Davis et al . ) , disclosing the conjugation of a number of hormones and enzymes to PEG and polypropylene glycol to produce physiologically active non-i munogenic compositions.
  • a PEG having at least one terminal hydroxy group is reacted with a coupling agent to form an activated PEG having a terminal reactive group. Id .
  • This reactive group can then react with the ⁇ - and e-amines of proteins to form a covalent bond.
  • the other end of the PEG molecule can be "blocked" with a non-reactive chemical group, such as a methoxy group, to reduce the formation of PEG-crosslinked complexes of protein molecules.
  • the activated PEG is one that can react with the variant under conditions that do not destroy Site 1 binding activity.
  • Site 2 binding activity must also be preserved.
  • activated PEGs that introduce a toxic linking group into the conjugate are usually avoided.
  • Suitable activated PEGs can be produced by a number of conventional reactions.
  • an N-hydroxysuccinimide ester of a PEG (M-NHS-PEG) can be prepared from PEG-monomethyl ether (which is commercially available from Union Carbide) by reaction with N,N ⁇ -dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) , according to the method of Buckmann and Merr, Makromol. Chem.. 182: 1379-1384 (1981) .
  • a PEG terminal hydroxy group can be converted to an amino group, for example, by reaction with thionyl bromide to form PEG-Br, followed by aminolysis with excess ammonia to form PEG-NH 2 .
  • the PEG-NH 2 is then conjugated to the protein of interest using standard coupling reagents, such as Woodward's Reagent K.
  • a PEG terminal -CH 2 OH group can be converted to an aldehyde group, for example, by oxidation with Mn0 2 .
  • the aldehyde group is conjugated to the protein by reductive alkylation with a reagent such as cyanoborohydride.
  • activated PEGs suitable for use in the present invention can be purchased from a number of vendors.
  • Shearwater Polymers, Inc. (Huntsville, AL) sells M-NHS-PEG as "SCM-PEG” in addition to a succinimidyl carbonate of methoxy-PEG ("SC-PEG”) and methoxy-PEG succinimidyl propionate (“SPA-PEG”; hereinafter referred to as "M-SPA-PEG” to indicate the presence of the methoxy blocking group) .
  • SCM-PEG succinimidyl carbonate of methoxy-PEG
  • SPA-PEG methoxy-PEG succinimidyl propionate
  • M-SPA-PEG methoxy-PEG succinimidyl propionate
  • Polymers also sells a branched-chain PEG having two 10,000 D chains (hereinafter "NHS-PEG2 (20, 000) , " the use of which is described in Example IX.
  • the degree of pegylation of an hGH variant of the present invention can be adjusted to provide a desirably increased in vivo half-life (hereinafter "half-life"), compared to the corresponding non- pegylated protein. It is believed that the half-life of a pegylated hGH variant typically increases incrementally with increasing degree of pegylation.
  • a wild-type hGH conjugate containing two PEG(5000) groups has about a 4-fold longer half-life in rats than the non-pegylated protein
  • a conjugate containing five PEG(5000) groups has about an ll-fold longer half-life
  • a conjugate containing seven PEG groups has about an 18-fold longer half-life.
  • the actual molecular weights of those PEG-wild-type hGH conjugates were approximately 33, 48, and 57 kD, respectively, as compared to 22 kD for the non- pegylated protein.
  • a conjugate containing two PEG(5000) groups has about a 3-fold lower potency in a cell-based dimerization assay than the non-pegylated protein
  • a conjugate containing five PEG(5000) groups has about a 170-fold lower potency
  • a conjugate containing seven PEG groups has about a 1500- fold lower potency. Because Site 1 binding is es ⁇ ential for agoni ⁇ t and antagoni ⁇ t hGH variant ⁇ of the present invention, increased pegylation reduces the potency of both types of hGH variants.
  • the increase in half-life generally compensates for the reduction in potency, so that the in vivo efficacy of pegylated hGH variants is presently believed to be comparable to, or better than, that observed with the corresponding non-pegylated proteins. Accordingly, one skilled in the art can readily determine a suitable degree of pegylation for an hGH variant to produce a conjugate having a desirably increased half-life, compared to the non- pegylated protein, yet retaining ⁇ ufficient potency to be efficaciou ⁇ in vivo .
  • the half-life is increased at least about five-fold; preferably, at least about 10-fold; more preferably, at least about 50-fold; and most preferably, at least about 100-fold.
  • the degree and sites of pegylation are such that the PEG- hGH variant conjugate is capable of binding hGH receptor at Site 1, typically with a K d of about 400 nM or lower; preferably, with a K d of 150 nM or lower; and more preferably, with a K d of 100 nM or lower, as measured by an equilibrium binding assay, such as that described in Spencer et al . , J. Biol. Chem.. 263 : 7862- 7867 (1988) .
  • Agonist PEG-hGH variant conjugates of the present invention are capable of binding at Site 2 as well as at Site 1, thus dimerizing hGH receptors. Dimerization capability can be measured, for example, by homoquenching of fluorescence, according to the method of Cunningham et al . , Science. 254 : 821-825 (1991), or in a cell-based dimerization assay, such as that described in Fuh et al . , Science. 256: 1677-1680 (1992) , and in Examples XI and XII. Conveniently, the EC 50 for pegylated agonist hGH variants, &s measured in the cell-based dimerization assay of Fuh et al .
  • Pegylated hGH variants that meet these criteria have an actual molecular weight of at least about 40 kD.
  • Exemplary conjugates include conjugates having about four to six, and preferably, five, molecules of PEG(5000) per molecule of hGH variant and conjugates having one molecule of PEG(20, 000) per molecule of hGH variant.
  • the degree and sites of pegylation of a protein are determined by (1) the number and reactivities of pegylation sites (i.e., primary amines) and
  • Wild-type hGH contains ten primary amines that are theoretically available to react with an activated PEG: the ⁇ -amino group of the N-terminal phenylalanine and the e-amino groups of nine lysines.
  • PEG poly(ethylene glycol)
  • standard pegylation reactions typically result in less than complete pegylation (e.g., seven or eight PEGs per molecule for wild-type hGH) .
  • the sites of pegylation of a protein are also somewhat constrained by the reactivities of the various primary amines.
  • a potential lysine in the Site 1 hormone-receptor binding interface of the B2036 variant (K41) is relatively unreactive with M-SPA- PEG(5000) .
  • M-SPA- PEG(5000) M-SPA- PEG(5000) .
  • moderately pegylated B2036 variant preparations having on the order of four to six PEGs per variant molecule, retain the ability to bind hGH receptor at Site 1, despite the presence of a potential pegylation site at this binding interface.
  • Standard mutagenesis techniques can be used to alter the number of lysines in the protein.
  • hGH variants of the present invention can contain a greater or lesser number of potential pegylation sites than wild-type hGH.
  • the B2036 variant contains nine potential pegylation sites, one fewer than wild-type hGH, whereas the B2024 variant contains ten potential sites. Furthermore, amino acid sub ⁇ titutions introducing or replacing lysines alter the locations of potential pegylation site ⁇ .
  • the K168A and the K172R substitutions reduce the number of sites available for pegylation at the hormone- receptor Site 1 binding interface.
  • the replacement of G120 with a different amino acid disrupts hGH binding at Site 2, converting the molecule to an hGH antagonist.
  • the substitution of lysine for glycine at this position provides an additional potential pegylation site in Site 2, which is expected to impair any residual binding at this site.
  • the reactivities of the primary amines in the B2036 variant are shown in Example X.
  • the degree and sites of pegylation can also be manipulated by adjusting reaction conditions, such as the relative concentrations of the activated PEG and the protein as well as the pH. Suitable conditions for a desired degree of pegylation can be determined empirically. Briefly, standard pegylation reactions are set up in which the above-noted parameters are varied. For example, hGH variant pegylation reactions (containing 10 mg/ml hGH variant in 0.05 M sodium borate buffer, pH 8.5) in which the number of equivalents of M-NHS-PEG(5000) per free amino group is varied between one and three produce the preparations shown below:
  • the phrase "equivalent per free amino group” refers to a molar amount of activated PEG equal to the molar amount of the molecule to be pegylated multiplied by the number of free amines in the molecule.)
  • preparations subjected to limited pegylation such as preparation 1
  • the protein is pegylated at the most reactive sites, whereas, if pegylation is more extensive (as in preparation 3) , less reactive sites are also pegylated.
  • hGH variants are pegylated with M-SPA- PEG(5000) .
  • M-SPA- PEG(5000) is added, with stirring, to an aqueous solution of hGH variant at room temperature.
  • the aqueous solution is buffered with a buffer having a pK a near the pH at which the reaction is to be carried out (generally about pH 4-10) .
  • suitable buffers for pegylation at pH 7.5 for instance, include HEPES, phosphate, borate, Tris-HCI, EPPS, and TES.
  • the pH is continuou ⁇ ly monitored and adjusted if necessary. The reaction is allowed to continue for about one to about two hours.
  • reaction products are then subjected to hydrophobic interaction chromatography to separate pegylated hGH variants from free M-SPA-PEG(5000) and any high-molecular weight complexes of the pegylated hGH variant.
  • High-molecular weight complexes arise when unblocked PEG is activated at both ends of the molecule, cros ⁇ linking hGH variant molecules.
  • the conditions during hydrophobic interaction chromatography are such that free M-SPA-PEG(5000) flows through the column, while any crosslinked pegylated hGH variant complexes elute after the desired form ⁇ , which contain one hGH variant molecule conjugated to one or more PEG group ⁇ . Suitable conditions vary depending on the relative size ⁇ of the cro ⁇ linked complexe ⁇ ver ⁇ us the desired conjugates and are readily determined by those skilled in the art.
  • the eluent containing the desired conjugates is concentrated by ultrafiltration and desalted by diafiltration.
  • This preparation represents a heterogeneous mixture of PEG-hGH variant conjugates having between three and six PEG groups per molecule of hGH variant.
  • this mixture i ⁇ ⁇ ubjected to an additional purification ⁇ tep that produce ⁇ a more homogeneous preparation of pegylated hGH variants.
  • the mixture is subjected to cation exchange chromatography to fractionate the pegylated hGH variants according to the extent of pegylation. The conditions are such that the more highly pegylated hGH variants having a greater number of PEG group ⁇ elute early in the gradient.
  • a "form" of a pegylated hGH variant is an PEG-hGH variant conjugate containing a particular number of PEG groups. Accordingly, different "forms" of a pegylated hGH variant have different numbers of PEG groups conjugated to the same hGH variant.
  • a pool of pegylated hGH variants is obtained that contains primarily two forms, namely, conjugates having 4 or 5 PEGs per molecule of hGH variant (hereinafter a "PEG-4/5-hGH variant preparation”) .
  • a composition containing a pegylated hGH variant for use in a therapeutic formulation can be heterogeneous or homogeneous, i.e., containing a single PEG-hGH form.
  • the composition contains at least 70% one or two forms of PEG-hGH variant conjugates; preferably, at least 80% one or two forms; and more preferably, at least 90% one or two forms.
  • Formulations of the hGH variants of the present invention for therapeutic administration are prepared for storage by mixing an hGH variant having the desired degree of purity with an optional pharmaceutically acceptable carrier, excipient, or stabilizer (Remington's Pharmaceutical Science ⁇ . 16th edition, Oslo, A., Ed., [1980]) in the form of a lyophilized cake or an aqueous solution.
  • Parenteral formulations can be prepared by mixing the hGH variant in a unit dosage injectable form (solution, suspension, or emulsion) with a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed and are compatible with other ingredients of the formulation.
  • the formulation preferably does not include oxidizing agents and other compounds known to be deleterious to polypeptides.
  • Suitable carriers include buffers containing phosphate, borate, HEPES, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; divalent metal ions such as zinc, cobalt, or copper; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactant ⁇ ⁇ uch a ⁇ Tween, Pluronics, or PEG.
  • Formulations of the present invention can additionally contain a pharmaceutically acceptable buffer, amino acid, bulking agent, and/or non-ionic surfactant.
  • a pharmaceutically acceptable buffer include, for example, buffers, chelating agents, antioxidants, preservatives, cosolvents, and the like; specific examples of these could include trimethyla ine salts (Tris buffer) and disodium edetate.
  • the GH formulation set forth in WO 89/09614 can be employed, wherein the hGH variant is contained in a composition comprising glycine, mannitol and a buffer, such as a phosphate buffer.
  • a buffer such as a phosphate buffer.
  • An exemplary version of this formulation is: 0.68 g/L glycine, 18.0 g/L mannitol, 5 mM sodium phosphate, pH 7.4.
  • the hGH variant can be contained in a liquid formulation that does not neces ⁇ arily contain mannitol or glycine and comprises 0.1 to 5% (w/v) of a non-ionic surfactant, such as polysorbate, or a poloxamer.
  • An exemplary version of this formulation is: 5 mg/ml hGH variant, 8.77 mg/ml NaCI, 2.5 mg/ml phenol, 2.0 mg/ml polysorbate 20, and 10 mM sodium citrate, pH 6.0.
  • sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
  • sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl- L-glutamate (U. Sidman et al . , Biopolymers. 22. 547-556 [1983]), poly(2-hydroxyethyl methacrylate) (Langer et al . , J. Biomed. Mater. Res..
  • Sustained-relea ⁇ e hGH variant compo ⁇ itions also include liposomally entrapped hGH variants. Liposomes containing hGH variants are prepared by methods known per se : DE 3,218,121; Epstein et al . , Proc. Natl. Acad. Sci. U.S.A., 82 . : 3688-3692 (1985); Hwang et al .
  • the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal hGH variant therapy.
  • the hGH variant can also be formulated for local administration. Suitable formulations vary depending on the site of administration and do not differ from those known in the art. For example, hGH can be formulated in a balanced salt solution for administration to the eye.
  • the hGH variant formulation for therapeutic administration is sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e . g . , 0.2 micron membranes) .
  • Therapeutic hGH variant compositions generally are placed into a container having a sterile access port, for example, an intravenou ⁇ solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • hGH variants ordinarily are stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
  • 5-ml vials are filled with
  • the infusion solution is prepared by reconstituting the lyophilized hGH variant using bacteriostatic water-for- injection and the like.
  • pegylated hGH variants of the present invention is carried out as described above for hGH variants generally.
  • the present invention includes variants that act as agonists of hGH and variants that act as antagonists of hGH, the latter containing a Site 2-disruptive mutation.
  • Agonist hGH variants are useful in increasing the anabolis or growth of a mammal.
  • Growth refers to the dynamics of statural growth experienced by an individual during infancy, childhood, and adolescence as depicted by a normal growth curve.
  • growth herein refers to the growth of linear- producing bone plate driven by chondrocytes, a ⁇ distinguished from the growth of osteobla ⁇ t cell ⁇ , derived from a different part of the bone. Restoration of normal growth patterns would allow the patient to approach a more satisfactory growth curve.
  • Examples of patients that are relatively resistant to GH but require treatment to induce an anabolic effect include those with Turner's Syndrome, GH-deficient children, children who experience a slowing or retardation in their normal growth curve about 2-3 years before their growth plate closes, that is, so-called short normal children, and patients where the insulin-like growth factor-I (IGF-I) response to GH has been blocked chemically (i.e., by glucocorticoid treatment) or by a natural condition such as in adult patients where the IGF-I response to GH is naturally reduced.
  • Immune disorders are also amenable to treatment with agonist hGH variants of the present invention.
  • immunoglobulin disorder includes any condition in which the immune system of humans as well as animals has a smaller antibody response to antigens than normal, whether because their spleen size is smaller than it should be, whether the spleen is only partially functional, whether drugs such as chemotherapeutic agents are suppressing the normal immune function, whether the animal is functionally IGF-I- (or GH-) deficient, or due to any other factor.
  • Examples include aged patients, patients undergoing chemotherapy or radiation therapy, recovering from a major illnes ⁇ , or about to undergo surgery, patients with AIDS, patients with congenital and acquired B-cell deficiencies such as hypogammaglobulinemia, common varied agammaglobulinemia, and selective immunoglobulin deficiencies, e . g.
  • An agonist hGH variant can act to stimulate the immune system of a mammal by increasing its immune function, whether the increase is due to antibody mediation or cell mediation, and whether the immune system is endogenous to the host treated with the hGH variant or is transplanted from a donor to the host recipient given the hGH variant (as in bone marrow transplants) .
  • the stimulation can result from an increased number of splenic cells such as splenic lymphocyte number, splenic T-cell population number (T-cell, CD 4 and CD g ) , or splenic B-cell number, or from an increased number of thymocytes.
  • splenic cells such as splenic lymphocyte number, splenic T-cell population number (T-cell, CD 4 and CD g ) , or splenic B-cell number, or from an increased number of thymocytes.
  • Other cells involved in the immune system response include natural killer cells, macrophages, and neutrophils.
  • the stimulation can be due to an increase in antibody production in response to an immunogen.
  • the agonist hGH variants of the present invention can also be used to stimulate heart function.
  • the antagonist hGH variants of the present invention are useful in treating conditions in which the inhibition of GH action is desirable.
  • Particularly amenable to treatment with antagonist hGH variants are conditions in which a reduction of circulating levels of GH or of a mediator of GH action, such as IGF-I, provides a therapeutic benefit.
  • Such conditions include conditions of GH excess such as, for example, giantism and acromegaly. Giantism results from GH excess before puberty, when the long bone growth is still possible. Acromegaly results from GH excess after puberty, when the long bones have fused.
  • Acromegaly is characterized by bony overgrowth and soft tis ⁇ ue swelling as well as hypertrophy of internal organs, especially the heart. Acromegaly is typically caused by a pituitary tumor that secretes GH. The hallmarks of the disease are high levels of circulating GH and IGF-I.
  • the antagonist hGH variants of the present invention are presently believed to offer a significant therapeutic benefit by inhibiting GH action.
  • the antagonist hGH variants are also useful in treating the other conditions in which the inhibition of GH action provides therapeutic benefit.
  • diabetes and its complications such as for instance diabetic retinopathy and diabetic nephropathy.
  • Diabetic retinopathy is characterized by proliferation of the cells making up the retinc.1 blood vessels, growth of new vessels on top of the retina (neovascularization) , development of microaneurysms, and leakage of fluid into the surrounding retinal tissue.
  • the early hallmarks of diabetic nephropathy are renal hypertrophy and hyperfiltration. As the disease progresses, diffuse enlargement of the mesangial cells (which support the filtration apparatus of the kidney) is observed, accompanied by an absolute increase in the number of mesangial cells.
  • Vascular eye diseases that, like diabetic retinopathy, involve proliferative neovascularization are also believed to be amenable to treatment with antagonist hGH variants. Examples include retinopathy of prematurity, retinopathy associated with sickle cell anemia, and age-related macular degeneration, which is the most common cause of vision los ⁇ in per ⁇ ons over 55.
  • GH-responsive malignancies include malignancies that respond to GH, or a mediator of GH action (such as IGF-1) , by growing (hereinafter "GH-responsive malignancies") .
  • GH-responsive malignancies include Wilm's tumor, various sarcomas (e.g., osteogenic sarcoma) , and breast, colon, prostate, and thyroid cancer.
  • the antagonist hGH variants of the present invention inhibit the growth of cells expres ⁇ ing receptors to which the variants bind. A wide variety of tissues express such receptors.
  • GH receptor mRNA is expressed in cell lines from normal placenta, thymus, brain, salivary gland, prostate, bone marrow, skeletal muscle, trachea, spinal cord, retina, lymph node and from Burkitt's lymphoma, colorectal carcinoma, lung carcinoma, lymphoblastic leukemia, and melanoma.
  • antagonist hGH variants of the present invention are generally useful in treating cancers that express receptors to which the variants bind.
  • the agonist or antagonist hGH variant is directly administered to the mammal by any suitable technique, including parenterally, and can be administered locally or systemically.
  • the specific route of administration depends, e.g., on the medical history of the patient, including any perceived or anticipated side effects using the hGH variant.
  • parenteral administration include subcutaneou ⁇ , intramu ⁇ cular, intravenous, intraarterial, and intraperitoneal administration.
  • the administration is by continuous infusion
  • the hGH variant is administered subcutaneously.
  • the administration can also be as a single bolus or by slow-release depot formulation.
  • the hGH variant composition to be used in the therapy is formulated and dosed in a fashion consistent with good medical practice, taking into account the specific condition being treated, the clinical condition of the individual patient (especially the side effects of treatment with hGH variant alone) , the site of delivery of the hGH variant composition, the method of administration, the scheduling of administra ⁇ tion, and other factors known to practitioners.
  • the "effective amount" of hGH variant for purposes herein is thus determined by such considerations.
  • the total pharmaceutically effective amount of the hGH variant administered parenterally per dose i ⁇ in the range of about 1 ⁇ g/kg/day to about 100 mg/kg/day of patient body weight, although, a ⁇ noted above, thi ⁇ is subject to therapeutic discretion. Usually, this dose is between about 0.01 and about 10 mg/kg/day, and more usually for humans between about 0.01 and about 1 mg/kg/day.
  • the hGH variant i ⁇ typically administered at a dose rate of about 1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by one to four injections per day or by continuous subcutaneous infusions, for example, using a mini-pump.
  • An intravenous bag solution can also be employed.
  • a ⁇ measured for agonists for example, by increases in long bone growth, antibody production, splenocyte or thymocyte number, and splenic B-cells, and as measured for antagonists, for example, by reduction in serum GH, serum IGF-I, and tumor growth, etc.
  • a pegylated hGH variant of the present invention can be administered by any of the routes of administration described above. However, it is presently believed that a pegylated hGH variant need not be administered as frequently as a non-pegylated hGH variant.
  • Non-pegylated hGH and hGH variant ⁇ are typically admini ⁇ tered at lea ⁇ t three times a week and often daily. However, the pegylated forms of these proteins can be administered between about once every three days to about once a month, or more typically between about once every 6-7 days to once every two weeks.
  • the mammals potentially treatable by the hGH variants herein include mammals of economic importance such as bovine, ovine, and porcine animals.
  • the preferred mammal herein is a human. The following is presented by way of example and is not to be construed as a limitation to the scope of the invention. All citations used herein are expressly incorporated herein by reference.
  • the hGHbp was immobilized in discrete orientations on the sensor chip by fixing the hGHbp via a free thiol. This was accomplished by introducing a cysteine residue at one of two specific sites (S201C or S237C) using site-directed mutagenesis (Kunkel et al . , supra ) .
  • the thiol variants of the hGHbp were expressed in E . coli and purified to homogeneity. Fuh et al . , J. Biol. Chem.. 265: 3111- 3115 (1990) .
  • the hGHbp variants were reacted with the matrix (at 50 ⁇ g/ml in 50 mM sodium acetate, pH 4.5) until approximately 1000 RU's were coupled (1.0 ng/mm 2 ; see the BIAcoreTM manual) .
  • Association rates were measured from binding profiles obtained by injecting increasing concentrations of each hGH variant. Five serial dilutions (each 2-fold) were made starting at 200 or 1000 nM hormone depending on the affinity for the hGHbp. A maximum flow rate of 20 ⁇ l/min. was applied to minimize potential mass transport effects. High salt buffer (150 mM NaCI, 10 mM sodium phosphate, pH 7.4) was used to prevent long-range electrostatic effects and to mimic physiological ionic strength. Also included was 0.02% Tween 20 to reduce non-specific binding. The matrix was regenerated by washing for 20 seconds with 4.5 M MgCl 2 . Control experiments showed this was sufficient to remove all the bound hormone, and the matrix could be re-used more than 50 time ⁇ without ⁇ ignificant change in the binding kinetics.
  • Dissociation rates were measured by saturating the biosensor with 5 ⁇ M hGH mutant and switching to buffer without hormone. Buffer flow rates and regeneration conditions were identical to those used to measure the association profiles. Potential rebinding effects were minimized by using only the initial 10 minutes of each dissociation profile for calculation of the dissociation constant. Both association and dissociation constants were determined using the Pharmacia Kinetics Evaluation software to solve the rate equations. Karlsson et al . , supra .
  • the average standard deviation within triplicate determinations of association constants on the same biosensor chip was ⁇ 4% of the value reported. Values determined between different biosen ⁇ or chips vary up to 60%. However, because a wild-type reference was always included, the standard errors for the relative values reported here are the same as determinations made on the same chip.
  • the concentration of hGH and variants was determined by densitometry of Coomassie blue- stained proteins after SDS polyacrylamide gel electrophoresi ⁇ . Thi ⁇ method confirms the purity and integrity of the variant hormones as well as providing a protein concentration independent of the substitution with a precision of ⁇ 10%. Cunningham and Wells, supra . Thus, the average cumulative errors in relative association, dissociation, and affinity constants are about 17%, 14%, and 21%, respectively.
  • the binding of hGH to the hGHbp was studied by immobilizing a variant of the hGHbp, (S237C)hGHbp [Ser237 is converted to Cys in the hGHbp] to the thiol- derivatized matrix on the BIAcoreTM biosensor via a mixed disulfide bond.
  • Fig. 1A The S237C(hGHbp) mutation does not affect binding affinity to hGH and has been used to attach a single thiol-specific fluorescent probe to follow hGH-induced dimerization of the hGHbp in solution. Cunningham et al . , 1991, supra .
  • Fig. IB From the change in RU, a molar ratio of 0.4 hGH bound per immobilized hGHbp was calculated. See Table 1. This indicateed that hGH dimerized the immobilized hGHbp as it did in solution.
  • Fig. 1A Dimerization on the matrix was further tested by measuring the binding to hGHbp of a non-dimerizing mutant of hGH, (G120R)hGH, which is blocked in its ability to bind Site 2. Fuh et al . , 1992, supra .
  • Hormone Matrix (hormone: hGHbp) (s'M 1 ) ( ⁇ - 1 ) (nM)
  • the (G120R)hGH had virtually the same kinetics as hGH on the (S201C)hGHbp-matrix and the same as that of (G120R)hGH on the (S237C)hGHbp- matrix (Table 1) . Together these data indicate that the (S201C)hGHbp-matrix is a reliable means of testing variants of hGH for binding to Site 1 alone.
  • a buried side-chain on hGH wa ⁇ defined a ⁇ one that contains side-chain atoms whose accessibility to solvent changes when bound to the hGHbp at Site 1.
  • Rate measure ⁇ ments were made using the hGHbp(S201C) matrix at 25°C as described in Table 1.
  • Shown in parenthese ⁇ is the area of each side-chain for atoms beyond the j ⁇ -carbon in hGH that become inaccessible to solvent once the receptor binds. 2
  • Total number of van der Waals contacts is the number of receptor atoms within 4.4 A of any atom beyond the j8-carbon of the contact side-chain based on inspection of the hGH(hGHbp) 2 complex. Over 80% of the contact distances are 3.8 to 4.2 A.
  • Groups making hydrogen bonds (h) or salt-bridges (s) are determined by donor- acceptor or complementary charge pairs within 3.3 A of each other between hGH and the hGHbp. For example, hN218 next to H18 indicates a H-bond between H18 on hGH and N218 of the hGHbp.
  • mc indicates an H-bond to a main-chain amide.
  • K j fAla mut) J J- ⁇ , (mut) K d (wt) k ⁇ /k ⁇ wt)
  • K ⁇ fAla mut 4
  • the ⁇ G values were calculated as +RTln K d (wt) from BIAcoreTM biosensor data or in parentheses from radioimmunoassay data that was previously reported. Cunningham and Wells, supra ; Cunningham and Wells, Proc. Nat. Acad. Sci. USA. 88: 3407-3411 (1991).
  • the (S201C)hGHbp-matrix was used to measure the affinities for alanine mutants at the 30 buried residues in the Site 1 interface (Table 2) .
  • Previously used was a radioimmunoprecipitation a ⁇ say (RIA) to measure the binding constants for many of these mutants. Cunningham and Wells, 1989 and 1991, supra .
  • RIA radioimmunoprecipitation a ⁇ say
  • the average standard error in affinity constant is about 20% for using the BIAcoreTM bio ⁇ en ⁇ or versus about 30% for the RIA. It is also possible that some dimerization of the hGHbp can occur in the RIA that would lead to systematic errors in affinities; this is prevented using the (S201C)hGHbp-matrix.
  • an hGH mutant with changes at H18, Q22, F25, D26, Q29, E65, K168, and E174 has increased binding affinity for hGHbp.
  • the variant with all alanine residue ⁇ at these position ⁇ i ⁇ calculated to have a binding affinity about 200-fold greater than that of wild-type hGH based on the additivity of individual amino acid changes.
  • an Asp at position 18 and/or a Ser at position 174 in this combination mutant would also have a significantly greater binding affinity toward hGHbp than wild-type hGH.
  • the off-rate effects are much larger than the on-rate effects (Table 2; Fig. 4) .
  • the conversion of three Arg side-chains (R64, R167, and R178) to Ala produced the greatest reductions in on- rate, but only about 2-fold.
  • the conversion of two Glu side-chains (E65 and E174) to Alo caused the greatest increases in on-rate (nearly 2-fold improved) . This indicates that electrostatic interactions are the most important ⁇ ide-chain determinants in guiding the hormone to the receptor.
  • the side-chains that most affect on-rate are not all the same as those that mo ⁇ t affect off-rate. Fig. 4.
  • R167A causes the largest decrease in on-rate but leads to a compen ⁇ ating decrea ⁇ e in off- rate.
  • Many of the alanine mutations at side-chains that dominate the affinity (P61A, K172A, T175A, and F176A) have virtually no effect on the association rate.
  • the preferred combination mutant from these experiments which has a 200-fold greater binding affinity for the GH receptor than wild-type hGH, resulting from the additivity of each mutation, has the sequence H18A,Q22A,F25A,D26A,Q29A,E65A,K168A,E174A.
  • Each of these side-chain ⁇ make ⁇ contacts between helix 1 and helix 4 that dominate the Site 1 epitope but are not directly involved in binding.
  • F54 and 158 disrupt affinity and are buried in the loop region that positions the second mini- helix.
  • This mini-helix contains R64 and other important binding determinants.
  • some minor effects on binding can result from structural perturbations that are propagated from alanine mutations near but not at the structural epitope.
  • the vast majority of residues tested away from the Site 1 structural epitope have no detectable effect on binding when converted to alanine. Cunningham and Wells, 1989, supra .
  • the alanine-scanning data ⁇ how only seven of 30 side-chains buried at the interface account for about 85% of the binding energy. Virtually all of the rest can be accounted for by six other side-chains. It has been attempted to correlate a number of structural parameters that can explain why some residues are critical for binding and others are not. The residues are found important for binding cluster in a small region near the center of the structural epitope
  • Thi ⁇ is because the mi ⁇ ing ⁇ ide-chain in the alanine mutant creates a cavity at the interface, and hence more surface area would be covered upon complex formation. Also calculated was the change in side-chain acces ⁇ ibility that occur ⁇ upon binding for atoms beyond the beta-carbon that was the criterion for defining buried ⁇ ide-chain ⁇ (see value in parentheses in column 2 of Table 2) . Yet a plot of these values versus the change in free energy gives no better correlation. A plot of the number of van der Waals contacts made by atoms of hGH beyond the beta-carbon versus the change in affinity when the side-chain is converted to alanine (Fig. 5B) does not show a good correlation either. Neither correlation improves by considering separately the side-chains that are capable of electrostatic interactions. Horton and Lewis, Protein Science. 1 ' 169-181
  • H-bond ⁇ Five of these are charged H-bond ⁇ (Q46, K168, E174, T175, R178) , yet the change in binding free energy when they are converted to alanine i ⁇ only +0.1, -0.2, -0.9, +2.0, and +2.0 kcal/mol, respectively, giving an average value of +0.6 kcal/mol.
  • the change in affinity for mutating the two neutral H-bonding side-chains (H18 and S62) is only - 0.5 and +0.1, respectively.
  • Three other side-chains form salt-bridges with the hGHbp (R64, R167, and D171) , yet these cause reductions of only +1.6, +0.3, and +0.8 kcal/mol, respectively. These values are less than ones estimated for two engineered salt bridges in subtilisin that range from +1.8 to +2.3 kcal/mol.
  • Some site-specific mutants of hGH were constructed by oligonucleotide-directed mutagenesis, using single- stranded template. Kunkel et al . , Methods Enzymol. , 204 : 125-139 (1991) .
  • the plasmid phGHam-g3 encoding wild-type hGH fused to the carboxy-terminal domain of M13 genelll (Lowman et al . , supra ) , was used to construct parental vectors for cassette mutagenesis.
  • Monovalent hGH-displaying phagemid particles were prepared (Lowman and Wells, supra ) by electro- transforming E .
  • DNA molecules encoding the soluble hormones were expressed in E . coli (Chang et al . , supra) , ammoniu - sulfate precipitated from osmotically shocked cell supernatants (Olson et al . , Nature. 293: 408 [1981]), and quantitated by laser densito etry of Coomassie- stained SDS-PAGE gels. Cunninghaii- et al . , supra . Some variants were further purified by ion-exchange chromatography on a Mono-Q column (Pharmacia-LKB Biotechnology, Inc.) .
  • oligonucleotide #718 5'-GCC ACC TGA TGT CTA AGA AAC-3'
  • Unique Sfil and Aatll sites were introduced into phGHam-g3 to create pH0779, using oligonucleotides #782 (5 '-TTT GAA GAG GCC TAT ATG GCC AAG GAA CAG AAG-3 ' ) (SEQ. ID NO.
  • a randomized cassette was constructed from the complementary oligonucleotides #822 (5'-TC CCG AAG GAG CAG NNS NNS TCG TTC NNS NNS AAC CCG CAG ACG T-3 ' ) (SEQ. ID NO. 4) and #823 (5'-CTG CGG GTT SNN SNN GAA CGA SNN SNN CTG CTC CTT CGG GAT AT-3 ' ) (SEQ. ID NO. 5) .
  • the parental DNA (pH0779) was digested with restriction enzymes Sfil and Aatll, and the large fragment was purified and ligated with the cassette.
  • the ligation products were electro-transformed into XLl-Blue cells for phagemid preparation in two aliquots, yielding 1 x 10 6 independent transformants each, as described by Lowman and Wells, supra .
  • Loop-A (residues 54-64) library of hGH
  • the existing Aatll site in phGHam-g3 was destroyed using oligonucleotide #718.
  • Unique Aatll and BstEII restriction sites were introduced in the hGH gene to construct pH0709, using oligonucleotides #719 (5'-AAC CCC CAG ACG TCC CTC TGT-3 ' ) (SEQ. ID NO. 6) and #720 (5'-GAA ACA CAA CAG TAA AGG TAA CCT AGA GCT GCT- 3') (SEQ. ID NO. 7).
  • oligonucleotide #536 (5 '-CGT CTT CAA GAG TTC AAC TTC TCC-3 ' ) (SEQ. ID NO. 8), to permit restriction-selection against possible contaminating clones from previous libraries (Lowman and Wells, supra) .
  • a randomized cassette was constructed from the complementary oligonucleotides #803 (5'-pCC CTC TGT NNS TCA NNS TCT NNS CCG ACA CCC AGT AAT NNS GAG GAA ACA CAA CAG AAG A-3 ' ) (SEQ. ID NO. 9) and # 804 (5'-pGTT ACT
  • the parental DNA (pH0709) was digested with restriction enzymes Aatll and BstEII , and the large fragment was purified and ligated with the cassette.
  • the ligation products were electro-tran ⁇ formed into XLl-Blue cell ⁇ for phagemid preparation in two aliquot ⁇ , yielding 1.6 x 10 6 and 1.0 x 10 6 independent tran ⁇ formant ⁇ .
  • DNA from the Helix-1 and the Helix-4b pools was purified and digested with the restriction enzymes AccI and BstXl .
  • the large fragment from each Helix-1 pool (randomly mutated at F10, M14 , H18, and H21) was then purified and ligated with the small fragment from each Helix-4b pool (randomly mutated at R167, D171, T175, 1179, in the E174S,F176Y background) to yield the three combinatorial libraries 707A (un-selected Helix-1 and Helix-4b pools) , 707B (twice-selected Helix-l pool with twice-selected Helix-4b pool) , and 707C (4-times selected Helix-l pool with 4-times selected Helix-4b pool) .
  • Duplicate ligations were also set up with one- tenth to one-half as much vector DNA and designated as 707D, 707E, and 707F, corresponding to the 0-, 2-, and 4-round starting libraries, respectively. All of these variant pools also contained the mutations E174S,F176Y obtained in earlier hGH-phagemid-binding selections. Lowman et al . , supra . The ligation products pH0707A-F were processed and electro-transformed into XLl-Blue cells.
  • hGH- phagemid particles were prepared and selected for hGHbp-binding over 2 to 7 cycles as described by Lowman et al . , supra .
  • hGH-phagemid DNA was purified and digested with the restriction enzymes EcoRI and BsfcXT.
  • each Helix-4b variant was then purified and ligated with the small fragment from each Helix-l variant to yield combined variants with mutations in both Helix-l and Helix-4b.
  • These variants were designated as AD, AE, AF, BD, BE, BF, CD, CE, CF to indicate the respective pairwise combinations of Helix-l (A, B, or C) and Helix-4b (D, E, or F) mutations.
  • the hGH variant 852d was constructed using BD a ⁇ template and the following oligonucleotides: #843 (5'-CAG ACC TCC CTC TGT CCC TCA GAG TCT ATT CCG-3 ' ) (SEQ. ID NO. 17) for adding F54P; #844 (5'-ACA CCC TCC AAC AAG GAG GAA ACA CAA CAG-3 ' ) (SEQ. ID NO. 18) for R64K; #846 (5'-CCA AAG GAA CAG ATT CAT TCA TTC TGG TGG AAC CCC CAG ACC TCC-3 ' ) (SEQ. ID NO. 19) for K41I,Y42H,L45W,Q46W.
  • Variant 852b was constructed using the same oligonucleotides with template phGHam-g3.
  • the equilibrium binding affinity for hGHbp was determined by assaying hGH variants in competition with 125 I-labeled hGH, labeled variant BD, or labeled variant 852d, in binding buffer: 50 mM Tris, pH 7.5, 10 mM MgCl 2 , 0.1% bovine serum albumin, 0.02% sodium azide. Lowman et al . , J. Biol. Chem.. 266: 10982-10988 (1991) . Immunoprecipitation of the hGH-hGHbp complex was carried out using a monoclonal antibody designated MAb5. Barnard et al . , Endocrinology. 115: 1805-1813 (1984) .
  • Dissociation constants were obtained by Scatchard analysi ⁇ . Cunningham and Wells, 1989, supra . Variants BD and 852d contain F176Y, which if iodinated could perturb the hormone-receptor interface. However, iodinated BD (cold) was indistinguishable from unlabeled BD in competing with l25 I-labeled BD for binding.
  • association and dissociation rate constants for hGH variants binding to immobilized hGHbp were obtained by measurement of ⁇ urface plasmon resonance (SPR) using a Pharmacia BIAcoreTM biosensor.
  • SPR ⁇ urface plasmon resonance
  • hGHbp is covalently coupled to a dextran matrix attached to a biosensor chip.
  • the hormone is maintained at constant concentration in a liquid phase pas ⁇ ing over thi ⁇ surface at a constant flow rate.
  • the in ⁇ trument measures the mas ⁇ of protein binding to the matrix in real time by sensing the change in SPR signal due to the change in refractive index near the biosensor surface. L ⁇ fas and Johnsson, J. Chem. Soc. Chem. Commun.. 21: 1526-1528 (1990).
  • hGHbp(S201C) A variant of hGHbp(S201C) was used as the immobilized species because binding of a second receptor on the matrix is blocked (see Example I) .
  • Dissociation rate constant ⁇ were obtained by plotting ln(R 0 /R,) v ⁇ t; association rate constant ⁇ were obtained by plotting [Slope of (dR,/dt) vs. R,] against hormone concentration (Karlsson et al . , supra) , or by plotting ln(dR t /dt) against hormone concentration using the BIAcoreTM biosensor kinetics evaluation software (Pharmacia Biosensor) . Equilibrium dissociation constants, K d 's, were calculated as ⁇ /k ⁇ ,.
  • Standard deviations, ⁇ , for k ⁇ and ⁇ off for k off were obtained from measurements with 2 or more series of 2-fold or 3-fold dilutions (k OT ) or with 2 or more concentrated (>5 ⁇ M) hormone samples (k off ) .
  • Receptor binding affinities of hGH alanine mutant ⁇ in wild-type background measured by BIAcoreTM ( + ) or by RIA (unmarked) and normalized relative to the RIA value for wild-type hGH as measured by Cunningham et al . , 1989, supra .
  • Alanine or glutamine mutations were made to test the contributions of side-chains in the Minihelix-l region of wild-type hGH. For comparison with the structural epitope, the number of van der Waals contacts with receptor is also shown, derived from the crystal structure of the hGH(hGHbp) 2 complex.
  • Helix-4a a library
  • E174S,F176Y the tightest binding mutant
  • Helix-4b the second library in which R167, D171, T175, and 1179 were randomly mutated in the E174S,F176Y background.
  • the phage selection studie ⁇ were expanded to the loop connecting helice ⁇ 1 and 2.
  • the four contact re ⁇ idue ⁇ in Minihelix-1 (K41, Y42, L45 and Q46) were randomized and representative clones were sequenced after 2 to 7 rounds of binding selection (Table 4) .
  • Some residue ⁇ were highly over-repre ⁇ ented at given positions compared to what was expected from the frequency of those residues in the starting library. For example, about 35% of the clones contained a Q46W mutation. This was 7.6 standard deviation units above a random chance occurrence for Trp in the library. This is a good way to score the pool of selectants to establish a consensus sequence because it accounts for the expected codon bias and sampling statistic ⁇ .
  • K41R a slight preference for Y42R or Y42Q
  • L45W or L45 a stronger preference for Q46W.
  • Consensus residues identified after sorting hGH-phagemid libraries The most frequently occurring residues from phage-displayed libraries are shown, based on fractional representation (P f ) among all sequenced clones after 2 to 7 rounds of binding selection.
  • Expected frequencies (P c ) were calculated from the number of NNS codons for each amino acid theoretically in the starting library.
  • Loop-A A second library (called Loop-A) was constructed in which F54, E56, 158 and R64 were randomly mutated. Alanine replacements caused a 4- to 20-fold reduction in affinity depending on the side-chain (Fig. 6A) . Despite the fact that R64 is the only one of these residues that makes direct contact with the receptor (Fig. 6B) , all positions showed a moderate to very strong preference for a particular residue that was usually different from the wild-type. R64K was the mo ⁇ t preferred (found in 81% of the clone ⁇ ) ; it i ⁇ known that R64K alone causes a " 3-fold improvement in binding affinity. Cunningham et al . , Science. 247: 1461-1465 (1990). After this the order of preference went F54P> I58T> E56D or E56W.
  • the binding affinitie ⁇ for many of the ⁇ e mutants were analyzed by expressing the free hormone in a non- suppressor host that terminates translation at the amber codon at the end of hGH and the start of the genelll domain.
  • Lowman et al . Biochemistry, supra .
  • This DNA sequence is expected to occur randomly at a frequency of one in a million clones, which demonstrates the power of the affinity selection. Similar results were obtained from the Loop-A library with the best isolate ⁇ being F54P,R64K and F54P,E56D,I58T,R64K, which are about 5-fold improved over wild-type hGH.
  • Variant C is also produced predominantly in disulfide dimer form too; however, the CD, CE, CF recombinants did not form a significant amount of dimer.
  • the BD variant had the greatest affinity, which was 30-fold tighter than wild-type hGH.
  • the tightest-binding variant from the Minihelix-1 library (K41I,Y42H,L45W,Q46W) and one of the tightest from the Loop-A library (F54P,R64K) were combined to produce the hexamutant, hGH 852b, whose affinity was about 40-fold higher than wild-type hGH. This was put together with the BD recombinant to yield the hGH variant, 852d, which bound about 400-fold tighter than wild-type hGH.
  • Binding constants were measured by competitive displace- ment of either '"i-labeled wild-type hGH, BD, or 852d, using hGHbp and Mab5 (Cunningham a d Wells, 1989, supra) .
  • K d (hGH) /K d (variant) K d (hGH) /K d (variant) .
  • Some affinities ( f ) are from Lowman et ai . , Biochemistry, supra .
  • BD, BF, CD, CE, CF represent combinations of these mutations.
  • 852b (K41I,Y42H,L45W,Q46W,F54P, R64K)
  • 852d BD
  • the highest affinity mutants isolated previously from the Helix-l library were F10A,M14W,H18D,H21N (Helix-l.B) and F10H,M14G,H18N,H21N (Helix-l.A); these bound about 3.3-fold and 2.4-fold tighter than wild-type hGH, respectively.
  • the Helix l.A sequence was recovered in 60% of the clones from Combinatorial Library A, and in 13% of the clones isolated in early rounds of sorting from Combinatorial Library B. The Helix-l.B sequence predominated in later rounds of sorting the Combinatorial Library B.
  • Combinatorial Libraries A, B and C In fact, one of the best mutants previously isolated (R167N,D171S,T175,I179T) was commonly isolated by combinatorial sorting and predominated especially in the later rounds. Some sequences sorted by combinatorial means were very different from ones selected from the two independent libraries; but this could arise for statistical reasons. For example, the Helix-l and Helix-4b libraries contain about 10° different DNA sequences, and if combined (without pre-selection) would contain 10 12 possible combinations. Transformation efficiencies limit the sampling size to less than or equal to -10 7 independent clones. Thus, the selection of the same sequences is remarkable given the high diversity of sequences possible in these libraries and the mild improvements in affinity being selected for.
  • this clone is identical to the BD variant (Table 6) , except that instead of D171S it contained the conservative substitution, D171A.
  • the 717B.1 and BD variants bound with comparable affinities (12 pM and 10 pM, respectively) .
  • the K41I,Y42H,L45W,Q46W variant bound 4.5-fold tighter than wild-type hGH.
  • Each of the single mutants in hGH caused 1.7- to 2.5- fold reductions in affinity.
  • Thio indicates that the combination of mutations at this site is critical for the affinity improvements. These residues lie on adjacent positions on one face of the minihelix-1.
  • Example I Effects of affinity maturation on the kinetics of binding
  • the BIAcoreTM biosensor device was used to measure the kinetics of binding for alanine mutants produced at residues in hGH that become buried at Site 1 upon receptor binding.
  • the BIAcoreTM biosensor was used to measure their kinetics of binding to the hGHbp (Table 9).
  • Table 9 In general, as the affinity from wild-type hGH was increased, the off-rate decreased with little change in on-rate. In fact, in going from wild-type to the highest affinity mutant, 852d, there was a >60-fold decrease in the off-rate and only a 4-fold increase in the on-rate.
  • the off-rate was too slow to measure accurately, but if it was calculated from the K d measured by RIA and the on-rate, the off-rate would be 100-fold slower than wild-type hGH.
  • the hGH binding site had previously been recruited into a homolog of hGH, human placental lactogen (hPL) . This differs in sequence by 15% from hGH and binds " 2000-fold weaker. Lowman et al . , J. Biol. Chem.. supra .
  • the recruited hPL variant has kinetic parameters for binding that are similar to hGH (Table 9) .
  • this mutant shows much larger improvement ⁇ in off-rate ("100-fold) compared to on-rate (about 10- fold) relative to wild-type hPL.
  • off-rate 100-fold
  • on-rate about 10- fold
  • Binding kinetics of hGH variants were carried out with immobilized hGHbp(S201C) in PBS buffer + 0.05% Tween-20.
  • the BIAcoreTM biosensor K d is calculated from k ⁇ /k ⁇ ,, except for hPL, for which k,,, and K d were measured and k off was calculated ( + ) .
  • the ratio of K d 's indicates the fold increase in binding affinity vs. wt-hGH according to the BIAcoreTM biosensor data. Mutant combinations in hGH are designated by Roman numerals.
  • the hPL (0274) contains V4I,D56E,M64R,E174A,M179I.
  • Regions of hGH were randomly mutated that were thought to be important either because they were in contact with the receptor or because when converted to alanine they affected binding affinity. Thus, an average random mutant from these libraries should be dramatically reduced in binding affinity from wild-type hGH. Yet after only a few rounds of selection, isolates bound with similar and often higher affinity than wild-type hGH. The clones isolated usually exhibited consensus sequence ⁇ that were different from the wild-type (Table 4) . Very small improvements in affinity led to rapid and almost exclusive convergence in these libraries. For example, the R64K mutant separately binds only about 3-times tighter than wild-type hGH (Cunningham et al . , 1990, supra) .
  • mutants that are misfolded or unstable can be either digested by proteases, aggregated, or blocked in secretion or assembly on phage.
  • mutations that are misfolded or unstable can be either digested by proteases, aggregated, or blocked in secretion or assembly on phage.
  • Cys-containing mutants which selection has been previously noted for hGH mutants (Lowman and Well ⁇ , supra) .
  • the number of codon ⁇ ⁇ imultaneou ⁇ ly mutated wa ⁇ deliberately limited to four (about 10 6 DNA sequences) so that there would be a good chance of having each represented in the starting pool of phage ids (about 10 7 independent transformants) .
  • K41, L45, R64, D171 and 1179 There is another group of functionally important residues that become highly buried upon receptor binding (K41, L45, R64, D171 and 1179).
  • K41, L45, R64, D171 and 1179 When these were randomized, improved substitutes were found that tended to be similar in character to the wild-type residue. For example, K41 was often replaced with Arg; L45 was substituted with large hydrophobic side-chains; R64 was most frequently substituted by Lys; D171 was optimally replaced by Asn and sometimes Ser; 1179 was usually substituted by 0-branched residues (Tables 4, 5, and 7; Lowman et al . , Biochemistry, supra) . Thus, improvements can be made at functionally important residues buried at the interface—they tend to be toward an isosteric side-chain or one of similar chemical character.
  • the F54P mutant enhances affinity by a factor of about 1.6 fold based on the fact that the double mutant (F54P,R64K) is improved in binding by 4.8 fold (Table 5) , and the R64K mutant alone enhances binding by a factor of ⁇ 3 (Cunningham et al . , 1991, supra) .
  • Residues 10 and 14 tend to co-vary, which is not surprising given their adjacent positions along helix 1.
  • the sum of the volumes of these two side-chains in the selectants tended to be the same or smaller than F10 plus M14. This is consi ⁇ tent with their tightly packed arrangement.
  • the residues where the most obvious improvements in affinity occurred were those that were shown by alanine-scanning mutagenesis to most affect binding.
  • the largest improvements in affinity came from R64K, E174S, and F176Y.
  • E174A was known to enhance affinity, but R64A and F176A caused large reductions in affinity.
  • the functional data can be more important for targeting residues for optimization than the structural data.
  • the B2036 Variant A further variant GH polypeptide was constructed with the intent of reducing potential immunogenicity by limiting the number of ⁇ ubstituted residue ⁇ in the polypeptide, yet maintaining enhanced binding affinity at site 1.
  • a second goal of this experiment was to limit the number of lysine residues occurring in the molecule, especially occurring at sites important in the binding of GH to its receptor, thereby rendering the variant a better candidate for modification with polyethylene glycol ("pegylation") , while preserving enhanced affinity of the variant for its receptor.
  • pegylation polyethylene glycol
  • the G120K substitution was added to generate a better antagonist candidate, although other substitutions at that position are acceptable. Any amino acid can be substituted at G120 to generate an antagonist; more preferably, the substitution is lysine, arginine, tryptophan, tyrot-ine, phenylalanine, or glutamate.
  • the R64K substitution was omitted so as to protect site I binding residues from pegylation.
  • the K168A and the K172R sub ⁇ titutions were added to B2036 to reduce the number of sites available for pegylation at the hormone-receptor site I binding interface. In contrast, the G120K sub ⁇ titution make ⁇ available an additional lysine for pegylation while providing an effective site 2 block.
  • substitution ⁇ in 852d were omitted from the construction of B2036 to reduce pos ⁇ ible antigenicity of the variant in humans. Although some reduction in affinity is expected in comparison to 852d, the expected affinity of B2036 for its receptor is still substantially greater than wild type and is desirable for use as an antagonist.
  • B2036 could be further modified by restoring the glycine at residue 120, thereby generating a candidate for use as an agonist that is expected to have reduced antigenicity in humans in comparison with 852d. Similarly, such a candidate would be more optimally pegylated, as the number of lysine residues within the site I interface is decreased in comparison with the "supermutant”.
  • EXAMPLE IV The B2024 Variant A further variant GH polypeptide was constructed with the intent of reducing potential immunogenicity by limiting the number of substituted residues in the polypeptide, yet maintaining enhanced binding affinity at site 1.
  • a second goal of thi ⁇ experiment wa ⁇ to limit the number of lysine residues occurring in the molecule, especially occurring at sites important in the binding of GH to its receptor, thereby rendering the variant a better candidate for modification with polyethylene glycol ("pegylation") , while preserving enhanced affinity of the variant for its receptor.
  • pegylation polyethylene glycol
  • alanine mutations were combined by site- directed mutagenesis to produce a growth hormone variant having a slower "off rate" from the growth hormone receptor than wild type growth hormone.
  • Variant B2024 thus has the following sequence:
  • the G120K substitution was added to make a better antagonist candidate, although other sub ⁇ titutions at that site are acceptable. Any amino acid can be substituted at G120 to generate an antagonist; more preferably, the substitution is lysine, arginine, tryptophan, tyrosine, phenylalanine, or glutamate.
  • B2024 could be further modified by restoring the glycine at residue 120, thereby generating a candidate for use as an agonist that is expected to have reduced antigenicity in humans. Similarly, such a candidate would be more optimally pegylated in comparison with 852d, as the number of lysine residue ⁇ within the ⁇ ite I interface is decreased in comparison with the "supermutant" .
  • EXAMPLE V Production of the B2036 Variant The B2036 variant was produced according to the following exemplary protocol.
  • Plasmid pMY223 is based on the well-characterized plasmid pBR322 and is similar to the hGH production plasmid pHGH4R (Chang, et al . , Gene. 5.5:189-196 [1987]), except that the B2036 coding sequence replaces the hGH coding sequence.
  • pMY223 encodes resistance to tetracycline antibiotics, but unlike pBR322 is sen ⁇ itive to ⁇ -lactam antibiotics (penicillin, ampicillin, etc) .
  • the B2036 variant is expressed from a 1106-bp expression cassette cloned into a Pstl-EcoRI restriction site.
  • the expres ⁇ ion ca ⁇ sette contain ⁇ a single copy of the B2036 variant coding sequence fused in frame to the 23-residue heat stable enterotoxin (STII) signal peptide (Picken, et al . , Infection and Immunity. 42 . :269-275 [1986]).
  • Transcription of B2036 variant is directed by the E . coli phoA promoter (Chang et al . , Gene, 44 . :121-125 [1986]) .
  • a translation initiation site is provided by the STII Shine-Dalgarno sequence. Translation begin ⁇ with the STII ⁇ ignal peptide, which direct ⁇ translocation of the B2036 variant across the cytoplasmic membrane into the periplasmic space. The STII signal peptide is then removed by E . coli leader peptidase. The mature protein folds into its correct conformation in the periplasm and both disulfide bonds are formed.
  • Plasmid pMY223 was constructed by a three-way ligation of fragments from plasmid ⁇ pB2036 and pHGH4R. More specifically, a 565 base pair (bp) N ⁇ il-PvuII fragment of pB2036 containing the B2036 variant coding sequence was ligated to the NsiI-BamHI backbone and the 405 bp PvuII-BamHI fragment of pHGH4R.
  • Pla ⁇ mid pB2036 was derived from plasmid pS0643, also known as phGHam-g3 (the construction of which is described in Lowman et al . , Biochemistry. 10:10832-10838 [1991]) , which was the starting plasmid employed in the phage display studies described in Example II.
  • pB2036 differs from pS0643 in that the B2036 coding sequence replace ⁇ the hGH coding sequence.
  • the host cell for expression of the B2036 variant was E . coli 33B6, which is a derivative of E .
  • E . coli W3110 see Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, :1 90-1219 [Washington, D.C.: American Society for Microbiology, 1987]).
  • the complete genotype of 33B6 is AfhuA phoAAE15 A (argF-lac) 169 deoC2 degP41 (APstI-Kan r ) II. (rrnD-rrnE) 1 ilvG2096(Val R ) .
  • the derivation of 33B6 is described below.
  • the starting strain, E . coli W3110 is a derivative of E. coli K-12 that is F " and lambda- resistant. It has been shown to carry an inversion of the chromosome between rrnD and rrnE.
  • the fhuA gene (previously designated tonA) was deleted from W3110 by imprecise excision of TnlO following its insertion into the fhuA gene.
  • the resulting strain, 1A2 is resistant to bacteriophages Tl, T5, and ⁇ 80.
  • phoAAE15 and A (argF- lac) 169 were simultaneously introduced into 1A2 by PI cotransduction with a linked Tn5 insertion in the proc gene. Precision excision of the transposon re ⁇ tored the proC gene.
  • the phoAAEl ⁇ mutation eliminate ⁇ alkaline pho ⁇ phata ⁇ e expre ⁇ sion, and the A (argF-lac) 169 mutation is respon ⁇ ible for the Lac- phenotype of thi ⁇ strain, 7C1.
  • the deoC2 mutation which eliminated deoxyribose phosphate aldolase expression, was introduced by Pi cotransduction.
  • the deoC locus is genetically linked to the threonine biosynthetic locus.
  • a threonine auxotroph was created by TnlO insertion and imprecise excision. The threonine auxotroph was then transduced to threonine prototrophy with Pi phage grown on a deoC2 mutant. Presence of the deoC2 mutation was confirmed by the inability of the resulting strain, 16C9, to grow on 0.2% thymidine as a carbon source.
  • the degP41 (APstI-Kan r ) , a mutation in the gene for a periplasmic protease, was introduced by transduction. This mutation was constructed in vitro by replacing a section of the degP gene with a kanamycin resistance gene. This is not a transposon, but allow ⁇ for ⁇ election of the deletion u ⁇ ing kanamycin resistance. The resulting strain is 23E3.
  • the ilvG2096 (Val r ) mutation was introduced by homogenotization. This mutation repairs a frameshift that causes the wild-type K-12 to be sensitive to valine.
  • Strain 23E3 was transformed with plasmid pAH29, containing the ilvG2096 (Val r ) marker and an ampicillin resi ⁇ tance gene.
  • a slurry of 33B6 cells containing the pMY223 vector (hereinafter "33B6/pMY223 cells”) for expressing the B2036 variant was produced as follows.
  • An amino acid feed for 1000-L fermentation was prepared by aseptically mixing the following components:
  • the fermentor was sterilized at 121°C for 30 minutes. After cooling, the following were aseptically transferred into the sterilized fermentor:
  • the fermentor was run at 37°C and pH was maintained at approximately pH 7.3 (i.e., between 7.0 and 7.5) with sufficient aeration and agitation to provide between 3 and 5 mM 0 2 /L-min.
  • 33B6/pMY223 cells were aseptically transferred to the fermentor as an 8-L inoculum with an optical density (OD) at 600 nm of 15.
  • the fermentor was run, feeding sufficient glucose to meet the culture's demand (but avoiding glucose accumulation in the fermentor) and maintaining the dissolved oxygen at 30% or more of air saturation. pH was controlled using 15 N ammonium hydroxide or 24% sulfuric acid, and FERMAX ADJUVANT 27 was used to control foaming.
  • the amino acid feed was begun at about 0.06 kg/minute.
  • the culture was inactivated by heat killing at 60°C for 30 seconds.
  • a cell slurry was then harvested by centrifugation and frozen in granules.
  • Frozen granules from the fermentation harvest (hereinafter the "cell pellet") were stored at -60°C or below prior to use.
  • 5 L extract buffer (6 M urea, 0.02 M Tris, pH 7.65, at room temperature) per kg cell pellet was added to a jacketed extraction tank. The cell pellet was slowly added to the extract buffer, with stirring. Foaming was minimized.
  • the suspension was mixed at 4°C until all of the pellet was in solution.
  • the pH was adjusted to 8.0 and the solution was mixed at 4°C for two hours to form an extract.
  • 3 L water per liter of extract and 10 ml 5% polyethylene imine (PEI) , pH 8.0, per liter of extract were added, with stirring.
  • PEI polyethylene imine
  • the extract was clarified by passage through an Alfa Laval AX213 continuous flow centrifuge.
  • the extract was continuously agitated to maintain the suspension and was fed at a rate of approximately 20 liters per minute (LPM) into the centrifuge.
  • LPM liters per minute
  • the supernatant was collected in a jacketed receiving tank, set to maintain the temperature at 4°C.
  • approximately 75 L of purified water (4°C) was fed through the centrifuge to recover the clarified E . coli extract from the centrifuge.
  • equilibration buffer 0.05 M Tris-HCI, pH 8.0, 4°C
  • the column was eluted with elution buffer (3 M urea, plus MES, MOPS, Tris-HCI, TEA-HC1, glycine and glycylglycine, each at 18 mM, pH 5.0).
  • elution buffer 3 M urea, plus MES, MOPS, Tris-HCI, TEA-HC1, glycine and glycylglycine, each at 18 mM, pH 5.0.
  • Column loading, wa ⁇ hing, and elution were carried out at a nominal flow rate for all chromatography ⁇ teps in this example.
  • Fractions of the UV-ab ⁇ orbing eluent were collected and analyzed by SDS-PAGE. Those fractions containing the B2036 variant were pooled.
  • the pH of the DEAE TRISACRYL LS PLUS pool was adjusted to about 7.2 with 2% sodium hydroxide at 4°C.
  • the column was washed and equilibrated with equilibration buffer (0.05 M Tris HCl, pH 8.0, 4°C) .
  • the column was then loaded with the pH-adju ⁇ ted pool and washed with at least three column volumes of equilibration buffer until the UV absorbance of the eluent was at or near baseline.
  • the column was eluted with elution buffer (3 M urea, plus MES, MOPS, Tris-HCI, TEA-HC1, glycine and glycylglycine, each at 18 mM, pH 5.0) , and fractions of the UV-absorbing eluent were collected and analyzed by SDS-PAGE. Those fractions containing the B2036 variant were pooled.
  • elution buffer 3 M urea, plus MES, MOPS, Tris-HCI, TEA-HC1, glycine and glycylglycine, each at 18 mM, pH 5.0
  • the pH of the DEAE SEPHAROSE FAST FLOW pool was adjusted to 7.2 with 2% sodium hydroxide at 4°C.
  • the column was equilibrated with equilibration buffer (0.05 M Tris, pH 8.0) and loaded with the pH-adjusted pool.
  • the column was washed with one column volume of equilibration buffer and eluted with a linear gradient starting at 0.05 M NaCI, 0.05 M Tris, pH 8.0 and ending with 0.20 M NaCI, 0.05 M Tris, pH 8.0, using three column volumes of each buffer. Fractions were collected and analyzed by SDS-PAGE, and those fraction ⁇ containing B2036 variant were pooled.
  • the column was equilibrated with three column volumes of equilibration buffer (0.75 M sodium sulfate, 0.05 M Tris, pH 7.2) through a 0.22 ⁇ inlet filter. The entire conditioned pool was then loaded onto the column through a 0.3 ⁇ Pall Profile inlet filter. The column was eluted with a linear gradient starting with 0.75 M sodium sulfate, 50 mM Tris, pH 7.2 and ending with 50 mM Tris, pH 7.5. Three column volumes of each buffer were used. Fractions were collected and analyzed by SDS-PAGE, and those fractions containing the B2036 variant were pooled.
  • a SEPHADEX G-25 column was used to reduce the salt in the PHENYL TOYOPEARL pool by exchanging the B2036 variant into 0.05 M Tris buffer.
  • the column was run at 4°C. The volume of the load was restricted to a maximum of 30% of the total bed volume of the column.
  • the column was equilibrated with three column volumes of equilibration buffer (0.05 M Tris, pH 7.2) and then loaded with the PHENYL TOYOPEARL pool.
  • the column was eluted with 0.05 M Tris, pH 7.2. When the OD at 280 nm began to increase, the pool was collected until the OD 280 fell to near baseline.
  • the column was eluted with approximately ten column volumes of elution buffer (2 M urea plus MES, MOPS, Tris-HCI, TEA-HC1, glycine, and glycylglycine, each at 17 mM, pH 5.0).
  • elution buffer 2 M urea plus MES, MOPS, Tris-HCI, TEA-HC1, glycine, and glycylglycine, each at 17 mM, pH 5.0.
  • the column was equilibrated with at least four column volumes of 0.1 M HEPES, pH 7.7.
  • the entire DEAE SEPHAROSE FAST FLOW pool was loaded onto the column, and the column was wa ⁇ hed with at least four column volumes of buffer.
  • the column was eluted with approximately two column volumes of elution buffer (0.1 M HEPES, 0.22 M NaCI, pH 7.7) . When the OD at 280 nm of the eluent exceeded 2.0, the pool was collected until the OD 280 fell below 2.0.
  • the B2036 variant was essentially free of host cell impurities and any known significant degraded forms of the variant as determined by SDS-PAGE using Coomassie blue stain.
  • the B2024 variant was produced according to the following exemplary protocol.
  • the B2024 variant was expressed in E . coli 33B6 using plasmid pMY216, which is the same as pMY223
  • a slurry of 33B6 cells containing the pMY223 vector (hereinafter "33B6/pMY216 cells") for expressing the B2024 variant was produced as follows. The following components were transferred to a 60-L fermentor capable of delivering 3-6 mM 0 2 /L-min:
  • the fermentor was run at 37°C and pH was maintained at approximately pH 7.0 (i.e., between 6.8 and 7.2) with sufficient aeration and agitation to provide between 3 and 6 mM 0 2 /L-min.
  • 33B6/pMY216 cells were aseptically tran ⁇ ferred to the fermentor a ⁇ an 1-L inoculum with an optical density (OD) at 600 nm of 4.
  • the fermentor was run, maintaining the dissolved oxygen at 0% of air saturation for as long as possible and feeding sufficient glucose to meet the culture's demand, but avoiding glucose accumulation in the fermentor.
  • Glucose was fed so that any acetate formed was reconsumed in a short time (usually less than a half hour, but not more than two hours) . pH was controlled using 12 N ammonium hydroxide containing 47 g/L L-leucine or 24% sulfuric acid, and FERMAX ADJUVANT 27 was used to control foaming.
  • the culture was inactivated by heat killing at 60°C for 30 seconds. A cell paste was then harvested by centrifugation and frozen.
  • Frozen cell paste from the fermentation harvest was stored at -60°C or below prior to use.
  • the cell paste was thawed overnight at 4°C.
  • 5 L extract buffer (6 M urea, 0.02 M Tris, pH 8.5, at 4°C) per kg cell paste was added to the cell paste.
  • the cells were homogenized in the buffer using an ULTRATURREX homogenizer (Tekmar, Cincinnati, OH) with stirring, minimizing foaming.
  • the temperature was maintained at 4°C, and the suspension was mixed until all of the cells were in suspension.
  • the pH was adjusted to approximately 8.1.
  • the solution was mixed at 4°C for two hours to form an extract. 1 L water per liter of extract and 20 ml 5% PEI, pH 8.0, per liter of extract were added, with ⁇ tirring.
  • the extract wa ⁇ clarified by passage through an Alfa Laval BTPX205 continuous flow centrifuge.
  • the extract was continuou ⁇ ly agitated to maintain the suspension and was fed at a rate of approximately 2 LPM into the centrifuge.
  • the supernatant was collected in a receiving tank at 4°C.
  • approximately 5-10 L of purified water (4°C) was fed through the centrifuge to displace the clarified E . coli extract from the centrifuge.
  • the clarified extract was diluted with purified water (4°C) until the conductivity measured less than 2.0 mS.
  • the DEAE TRISACRYL LS PLUS column was then loaded with the clarified E . coli extract. The columns were washed with at least three column volumes of equilibration buffer until the UV absorbance of the eluent was at or near baseline. The DEAE TRISACRYL LS PLUS column was then disconnected from the DEAE SEPHAROSE FAST FLOW column. The B2024 variant was eluted from the DEAE SEPHAROSE FAST FLOW column with a pH gradient elution buffer (3 M urea, plus MES, MOPS, Tris-HCI, TEA-HCl, glycine, and glycylglycine, each at 10 mM, pH 5.0).
  • a pH gradient elution buffer (3 M urea, plus MES, MOPS, Tris-HCI, TEA-HCl, glycine, and glycylglycine, each at 10 mM, pH 5.0).
  • the pH of the DEAE SEPHAROSE FAST FLOW pool was adjusted to pH 8.5 with 2% sodium hydroxide at 4°C.
  • the column was equilibrated with equilibration buffer (0.02 M Tris, pH 8.5), loaded with the pH-adjusted pool, and was eluted with a linear gradient starting at 0.02 M Tris, pH 8.5 and ending with 0.10 M NaCI, 0.08 M MES, pH 6.5, using 2.5 column volumes of each buffer. Fractions were collected and analyzed by SDS-PAGE, and those fractions containing B2024 variant were pooled.
  • the Q SEPHAROSE FAST FLOW pool was conditioned with conditioning buffer (2 M ammonium sulfate, 0.04 M Tris, pH 7.2) by adding a volume of conditioning buffer equivalent to the volume of the Q SEPHAROSE pool and stirring the resultant solution until uniform. The solution was then brought to room temperature.
  • the column was equilibrated with two to three column volumes of equilibration buffer (1.0 M ammonium sulfate, 0.02 M Tris, pH 7.2).
  • a SEPHADEX G-25 column was used to reduce the salt in the PHENYL TOYOPEARL pool by exchanging the B2024 variant into 0.02 M Tris buffer.
  • the column was run at 4°C. The volume of the load was re ⁇ tricted to a maximum of 30% of the total bed volume of the column.
  • the column was equilibrated with three column volumes of equilibration buffer (0.02 M Tris, pH 8.0) and then loaded with the PHENYL TOYOPEARL pool.
  • the column was eluted with 0.02 M Tris, pH 8.0. When the OD at 280 nm increased to approximately 0.2, the pool was collected until the OD 280 fell below 0.2.
  • the column was eluted with approximately ten column volumes of elution buffer (2 M urea plus MES, MOPS, Tris-HCI, TEA-HCl, glycine, and glycylglycine, each at 10 mM, pH 5.0).
  • elution buffer 2 M urea plus MES, MOPS, Tris-HCI, TEA-HCl, glycine, and glycylglycine, each at 10 mM, pH 5.0.
  • the DEAE SEPHAROSE FAST FLOW pool wa ⁇ concentrated on a DEAE SEPHAROSE FAST FLOW column (volume 0.06 L/g protein) run at 4°C.
  • the OD at 280 nm of the eluent exceeded 2.0, the pool was collected until the OD 280 fell below 2.0.
  • the B2024 variant was essentially free of host cell impurities and any known significant degraded forms of the variant as determined by SDS-PAGE using Coo assie blue stain.
  • Pegylation of the B2036 Variant With PEG(5000) M-SPA-PEG(5000) was used to pegylate the B2036 hGH variant.
  • Pegylation of the B2036 variant was carried out according to the following protocol, which is also suitable for pegylation of wild-type hGH and other hGH variants, such as the B2024 variant.
  • Purified B2036 variant produced a ⁇ set forth in Example IV, was reacted with M-SPA-PEG(5000) (Shearwater Polymers, Inc., Huntsville, AL) , which was added as a solid to the B2036 variant preparation.
  • the reaction was allowed to proceed at room temperature with constant stirring. Briefly, the B2036 variant preparation was diluted with 0.1 M HEPES, pH 7.7, to a final protein concentration of 10 mg B2036 variant/ml and allowed to come to room temperature. The pH of the room temperature solution was about 7.5. Solid M-SPA- PEG(5000) was added to the preparation, with stirring, to a concentration of 20 g/L. The pH was maintained at 7.5 ⁇ 0.1. The reaction was complete within two hours after the addition of M-SPA-PEG(5000) .
  • the pegylated B2036 variant preparation wa ⁇ conditioned by adding a volume of citrate conditioning solution (0.8 M sodium citrate, 0.05 M Tris, pH 7.7) equivalent to the volume of the pegylated B2036 variant preparation and stirring the resultant solution for about 15 minutes at room temperature.
  • the column was equilibrated at room temperature with at least one column volume of equilibration buffer (0.40 M sodium citrate, 0.05 M Tris, pH 7.5).
  • the conditioned pegylated B2036 variant preparation was then loaded onto the column.
  • the column was eluted with a four column volume linear gradient starting with 0.40 M sodium citrate, 50 mM Tris, pH 7.5, and ending with 50 mM Tris, pH 7.5.
  • Column loading, washing, and elution were carried out at a nominal flow rate for all chromatography step ⁇ in this example. Fractions were collected and analyzed by SDS-PAGE, and tho ⁇ e fraction ⁇ containing the PEG-B2036 variant conjugate were pooled.
  • the PHENYL TOYOPEARL pool wa ⁇ concentrated approximately three-fold and then diafiltered against six volumes of 0.025 M sodium acetate, pH 4.0, using an ultrafiltration system equipped with a 10 kD regenerated cellulose membrane (Millipore, Bedford, MA) .
  • the first step of the concentration was a total recycle with the filtrate open mode using the PHENYL TOYOPEARL pool. The recycle was done for about
  • the concentrated PHENYL TOYOPEARL pool was diafiltered against six volumes of 0.025 M sodium acetate, pH 4.0, in the DF mode (i.e., with the retentate directed to the recycle tank, filtrate directed to drain, and buffer transferred into the recycle tank) .
  • a transition from the UF mode to the DF mode is done automatically without a feed pump shutdown.
  • a low pres ⁇ ure drop ( ⁇ P) recycle wa ⁇ done in a total recycle with the filtrate clo ⁇ ed mode.
  • the retentate valve was fully open during this step.
  • the feed rate was maintained to give a 5 PSI pres ⁇ ure drop.
  • the recirculation was done for at least 10 minutes.
  • the product tran ⁇ fer mode wa ⁇ then u ⁇ ed to transfer the contents of the ultrafiltration sy ⁇ tem into a pool tank.
  • the transfer was done in two steps. The first step involved draining the retentate in the recycle tank through a valve, with the membrane unit isolated.
  • the ultrafiltration set-up was completely emptied, using a low-pressure stream of inert gas to pu ⁇ h the product out of the ⁇ ystem and into the pool tank.
  • the pegylated B2036 variant was further purified by cation exchange chromatography on an S SEPHAROSE FAST FLOW column, loading no more than 7 g protein/L resin.
  • the column was equilibrated at room temperature with at least three column volumes of 0.025 M sodium acetate, pH 4.0.
  • the entire PEG-B2036 variant UF/DF pool was then loaded onto the column, and the column was eluted with a seven column volume linear gradient starting with 0.025 M sodium acetate, pH 4.0, and ending with 0.25 M NaCI, 0.025 M sodium acetate, pH 4.0.
  • the S SEPHAROSE FAST FLOW pool was concentrated to approximately 10 g/L using an ultrafiltration system equipped with a 10 kD regenerated cellulose membrane (Millipore, Bedford, MA) . Concentration, low pressure drop recycle, and product transfer steps were performed as described in the "Ultrafiltration/Diafiltration" section above to achieve a seven-fold reduction in retentate volume.
  • a SEPHADEX G-25 column run at 4°C, was used to exchange the PEG-B2036 variant preparation into formulation buffer (18.0 g/L mannitol, 0.68 g/L glycine, 5 mM sodium phosphate, pH 7.4) .
  • the volume of the load was restricted to 25% of the total bed volume of the column.
  • the column was washed with one column volume of purified water for irrigation, followed by equilibration with at least 1.5 column volumes of formulation buffer.
  • the entire PEG-B2036 variant UF pool was then loaded onto the column, and the column was eluted with formulation buffer. When the OD at 280 nm exceeded 0.5, fractions were collected until the OD 280 fell below approximately 0.5.
  • the SEPHADEX G-25 pool was then diluted with formulation buffer to a concentration of 5.0 mg/ml.
  • the B2036 variant was pegylated with PEG(20, 000) according to the following exemplary protocol.
  • B2036 variant purified as described in Example V, was buffer exchanged into 0.05 M sodium phosphate, pH 7.5, using a G-25 SEPHADEX PD-10 column (Pharmacia, Piscataway, NJ) .
  • the B2036 variant solution was then diluted to a protein concentration of 10 mg/ml.
  • 60 mg of M-SPA-PEG(20,000) Shearwater Polymers, Inc. Huntsville, AL
  • the reaction was incubated at room temperature for 75 minutes.
  • the reaction mixture was buffer exchanged into 25 mM sodium acetate, pH 4.0, using a G-25 SEPHADEX PD 10 column.
  • the resultant PEG(20,000) -B2036 variant solution was applied to a SP SEPHAROSE HP column (Pharmacia) that had been washed with 25 mM sodium acetate, pH 4.0, until the column was equilibrated.
  • the column was loaded with the PEG (20,000) -B2036 variant ⁇ olution at a concentration of 4.1 mg/ml resin at room temperature.
  • the column was then eluted with a linear gradient consisting of 25 mM sodium acetate, pH 4.0, to 0.5 M sodium chloride in 25 mM sodium acetate, pH 4.0, using five column volumes of each buffer.
  • Fractions were collected and analyzed by SDS gel electrophoresis, using 2-15% polyacrylamide prepoured Daiichi gels (Owl Scientific, Cambridge, MA) . Fractions containing a PEG(20,000) -B2036 form having a single PEG(20,000) molecule conjugated to each B2036 molecule were pooled and concentrated by ultrafiltration using a CENTRIPREP 10 concentrator (Amicon, Inc., Beverly, MA) . The
  • CENTRIPREP 10 concentrator was centrifuged at 8,000 rpm in a SORVALL RT6000B centrifuge (Dupont Instruments, Newtown, CT) at 16°C. The retentate was removed and further concentrated using a CENTRICON 10 concentrator (Amicon, Inc) . The concentrator was centrifuged at 6500 rpm in a SORVALL RC-5B centrifuge at 16°C.
  • the concentrated PEG(20,000) -B2036 variant was then buffer exchanged into formulation buffer (18.0 g/L mannitol, 0.68 g/L glycine, 5 mM sodium phosphate, pH 7.4) using a G-25 SEPHADEX PD-10 column at room temperature.
  • B2036 variant purified as described in Example V, was buffer exchanged into 0.05 M sodium phosphate, pH 7.5, using a G-25 SEPHADEX PD-10 column (Pharmacia, Piscataway, NJ) .
  • the B2036 solution was then diluted to a protein concentration of 10 mg/ml.
  • 100 mg of NHS- PEG2(20,000) (Shearwater Polymers, Inc.) was weighed out in a tube, and 4 ml of the B2036 solution was added. The reaction was incubated at room temperature for 90 minutes.
  • the reaction mixture wa ⁇ buffer exchanged into 25 mM ⁇ odium acetate, pH 4.0, u ⁇ ing a G-25 SEPHADEX PD 10 column.
  • the resultant PEG2 (20,000) -B2036 variant solution was applied to a SP SEPHAROSE HP column (Pharmacia) that had been washed with 25 mM sodium acetate, pH 4.0, until the column was equilibrated.
  • the column was loaded with the PEG (20, 000) -B2036 variant solution at a concentration of 2.75 mg/ml resin at room temperature.
  • the column was then eluted with a linear gradient consisting of 25 mM sodium acetate, pH 4.0, to 0.5 M sodium chloride in 25 mM sodium acetate, pH 4.0, using five column volumes of each buffer.
  • Fraction ⁇ were collected and analyzed by SDS gel electrophoresis, using 2-15% polyacrylamide prepoured Daiichi gels (Owl Scientific, Cambridge, MA) .
  • Fractions containing a PEG2 (20,000)-B2036 form having a single PEG2(20,000) molecule conjugated to each B2036 molecule were pooled and concentrated by ultrafiltration using a CENTRICON 10 concentrator (Amicon, Inc., Beverly, MA). The concentrator was centrifuged at 6500 rpm in a SORVALL RC-5B centrifuge at 16°C. (Dupont Instruments, Newtown, CT) .
  • the concentrated PEG2 (20,000) -B2036 variant was buffer exchanged into formulation buffer (18.0 g/L mannitol, 0.68 g/L glycine, 5 mM sodium phosphate, pH 7.4) using a G-25 SEPHADEX PD-10 column at room temperature.
  • PEG-4/5-B2036 variant preparation produced as described in Examples V and VII were analyzed by tryptic mapping.
  • Purified PEG-4/5-B2036 variant samples (1 mg/ml in 1 M CaCl 2 , 0.1 M sodium acetate, 10 mM Tris, pH 8.8) were incubated with bovine trypsin (Worthington Biochemical Corp., Freehold, NJ) at a protein weight ratio of 1:40 (trypsin:PEG-4/5-B2036 variant) as described in Kohr, W.J. et al . , Anal. Biochem.. 122:348-359 (1982) .
  • the trypsin was added at time 0 and again at four hours of digestion. After incubation for eight hours at 37°C, digestion was stopped by adding phosphoric acid to pH 2, and samples were stored at 4°C.
  • Digested samples (100 ⁇ g) were loaded onto a 15 x 0.46 cm C-18 column (5- ⁇ m bead, 100-A pore size; NUCLEOSIL, Alltech Associate ⁇ , Deerfield, IL) in
  • K41 and K115 were determined to be unreactive, based on the failure to detect modified version ⁇ of the corresponding tryptic peptides.
  • Residue ⁇ 168 and 172 in the B2036 variant were not capable of reacting with PEG becau ⁇ e the ly ⁇ ines at these position ⁇ were replaced with different amino acid ⁇ . None of the mo ⁇ t reactive residues are in Site 1.
  • the three Site 1 lysines present in wild-type hGH (K41, K168, and K172) are unreactive (K41) or absent from B2036 (K168 and K172) .
  • pegylation of the B2036 variant does not directly block Site 1 binding.
  • EXAMPLE XI Cell-Based Assay of Agonist Activity of Pegylated B2036 A PEG-4/5-B2036 variant preparation produced as described in Examples V and VII was tested for activity in the cell-based dimerization assay described in Fuh, G. et al . , Science. 256:1677-1680 (1992) and Colosi, P. et al . , J. Biol. Chem.. 268:12617-12629 (1993) .
  • the full-length hGH receptor was stably transfected into a premyeloid cell line, FDC-Pl (Colosi, P. et al . , J. Biol. Chem..
  • EXAMPLE XII Cell-Based Assay of Antagonist Activity of Pegylated B2036 In a study designed to test antagonist activity, the non-pegylated B2036 variant and PEG-4/5-B2036 variant preparation, produced as described in Examples V and VII, were incubated with 11 ng/ml recombinant hGH and increasing concentrations of variant (10 4 cells/ 0.2 ml total assay volume). The concentration of variant required to block 50% of the recombinant hGH- stimulated cell proliferation, i.e., the half-maximal inhibitory concentration (IC 50 ) , was calculated for both variants. The IC 50 for non-pegylated B2036 wa ⁇ 0.19 ⁇ g/ml, whereas the IC 50 for PEG-4/5-B2036 was 13.01 ⁇ g/ml.
  • hGH variant preparation formulated in 18.0 g/L mannitol, 0.68 g/L glycine, 5 mM sodium phosphate, pH 7.4, were injected subcutaneously into two adolescent male Rhesu ⁇ monkey ⁇ per treatment group.
  • IGF-1 level ⁇ were determined by immunoa ⁇ say, as described in Amer. J. Primatology. 11 . : 53-62 (1986) . The results are shown in Fig. 11. Decreases in IGF-I levels were observed at seven days after administration for all monkeys treated with an hGH variant, with the most significant decrease observed in monkeys treated with PEG-4/5-B2036.
  • IGF-I levels had returned to pretreatment levels in monkeys treated with the G120K variant and the B2024 variant.
  • Reduced IGF-I levels were observed in monkeys treated with the pegylated forms of the G120K and B2024 variants and with the non-pegylated B2036 variant.
  • the 14-day IGF-1 level ⁇ for monkeys treated with PEG-4/5- B2036 variant preparation were the same as on day seven.
  • 21-day IGF-I levels were approximately the same as seven-day IGF-I levels for all treatment groups.
  • EXAMPLE XIV In Vivo Antagonist Activity of PEG-4/5-B2036 Variant Preparation: Single-Dose Pharmacodynamics The effect of a single injection of a PEG-4/5- B2036 variant preparation on IGF-I levels was studied in Rhesus monkeys. A single dose of 1 mg/kg PEG-4/5- B2036 variant preparation, produced as described in Examples V and VII and formulated in 18.0 g/L mannitol, 0.68 g/L glycine, 5 mM sodium phosphate, pH 7.4, was injected either intravenously or subcutaneously into adolescent male Rhesus monkeys. The placebo was 0.5 ml formulation buffer administered subcutaneously.
  • IGF-1 levels were determined as in Example XIII. The result ⁇ are ⁇ hown in Fig. 12. Regardle ⁇ of route of administration, the IGF-I levels of all monkeys treated with the PEG-4/5-B2036 variant preparation were reduced at one day after administration, continued to decrease until four days after administration, and remained low throughout the seven-day study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP96931597A 1995-09-21 1996-09-20 Varianten des menschlichen wachstumshormons Expired - Lifetime EP0851925B1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK05007536.5T DK1568772T3 (da) 1995-09-21 1996-09-20 Varianter af humant væksthormon
EP05007536A EP1568772B1 (de) 1995-09-21 1996-09-20 Varianten des menschlichen Wachstumshormons
EP05007535A EP1568771A3 (de) 1995-09-21 1996-09-20 Varianten des mensclichen Wachstumshormons

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53706795A 1995-09-21 1995-09-21
US53706895A 1995-09-21 1995-09-21
US537067 1995-09-21
US537068 1995-09-21
PCT/US1996/014830 WO1997011178A1 (en) 1995-09-21 1996-09-20 Human growth hormone variants

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP05007536A Division EP1568772B1 (de) 1995-09-21 1996-09-20 Varianten des menschlichen Wachstumshormons
EP05007535A Division EP1568771A3 (de) 1995-09-21 1996-09-20 Varianten des mensclichen Wachstumshormons

Publications (2)

Publication Number Publication Date
EP0851925A1 true EP0851925A1 (de) 1998-07-08
EP0851925B1 EP0851925B1 (de) 2005-08-03

Family

ID=27065361

Family Applications (3)

Application Number Title Priority Date Filing Date
EP05007536A Expired - Lifetime EP1568772B1 (de) 1995-09-21 1996-09-20 Varianten des menschlichen Wachstumshormons
EP96931597A Expired - Lifetime EP0851925B1 (de) 1995-09-21 1996-09-20 Varianten des menschlichen wachstumshormons
EP05007535A Withdrawn EP1568771A3 (de) 1995-09-21 1996-09-20 Varianten des mensclichen Wachstumshormons

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05007536A Expired - Lifetime EP1568772B1 (de) 1995-09-21 1996-09-20 Varianten des menschlichen Wachstumshormons

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05007535A Withdrawn EP1568771A3 (de) 1995-09-21 1996-09-20 Varianten des mensclichen Wachstumshormons

Country Status (14)

Country Link
US (4) US5849535A (de)
EP (3) EP1568772B1 (de)
JP (2) JP3628333B2 (de)
AT (2) ATE455171T1 (de)
AU (1) AU718439B2 (de)
CA (2) CA2658039A1 (de)
DE (5) DE851925T1 (de)
DK (2) DK1568772T3 (de)
ES (2) ES2190388T3 (de)
HK (1) HK1012508A1 (de)
LU (1) LU91204I2 (de)
NL (1) NL300210I2 (de)
PT (1) PT1568772E (de)
WO (1) WO1997011178A1 (de)

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU5132900A (en) * 1999-05-12 2000-11-21 Xencor, Inc. Novel nucleic acids and proteins with growth hormone activity
US6946265B1 (en) 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE10005301A1 (de) 2000-02-07 2001-08-09 Trutnau Hans Heinrich Multi-Schritt-Kinetik molekularer Interaktionen als analytisches Mess- und Auswerte-Verfahren
GB0011459D0 (en) * 2000-05-12 2000-06-28 Univ Wales Medicine Sequences
WO2001085993A2 (en) * 2000-05-12 2001-11-15 University Of Wales College Of Medicine Method for detecting growth hormone variations in humans, the variations and their uses
EP1284987B1 (de) * 2000-05-16 2007-07-18 Bolder Biotechnology, Inc. Verfahren zur rückfaltung von proteinen mit freien cysteinresten
EP1290170A2 (de) 2000-06-16 2003-03-12 Asterion Limited Bindungsreagenzien: chimäre ligand/rezeptorproteine
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
CA2428114C (en) * 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ATE353976T1 (de) * 2001-06-05 2007-03-15 Auckland Uniservices Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
CA2450473C (en) 2001-06-14 2011-11-15 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
IL161051A0 (en) 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CN101724075B (zh) * 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US20040161802A1 (en) * 2001-10-30 2004-08-19 Applied Molecular Evolution Methods for producing and improving therapeutic potency of binding polypeptides
EP1451368A4 (de) * 2001-11-09 2006-02-22 Pharmacia & Upjohn Co Llc Einzelnukleotid-polymorphe von gh-1
CA2463639A1 (en) * 2001-11-12 2003-05-22 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
PL374354A1 (en) * 2001-11-20 2005-10-17 Pharmacia Corporation Chemically-modified human growth hormone conjugates
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
US20040048315A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ZA200502320B (en) * 2002-09-20 2006-10-25 Pharmacia Corp Process for decreasing aggregate levels of pegylated protein
ATE453662T1 (de) * 2002-09-20 2010-01-15 Pharmacia Corp Verfahren zur verringerung der aggregatmengen des pegylierten proteins
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
CA2423904A1 (en) * 2002-12-19 2004-06-19 University Of Wales College Of Medicine Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
WO2004090135A2 (en) * 2003-04-09 2004-10-21 Asterion Limited Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
CA2547140A1 (en) * 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
NZ548123A (en) * 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US20060026719A1 (en) 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP1715895A2 (de) * 2004-02-09 2006-11-02 Pharmacia Corporation Chemisch modifizierte menschliche wachstumshormon-rezeptor-antagonisten-konjugate
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1751177A4 (de) 2004-04-19 2008-07-16 Univ Ohio Vernetzbare glycoproteine und verfahren zu ihrer herstellung
CA2567813C (en) 2004-05-23 2015-11-24 Gerard M. Housey Theramutein modulators
JP2008503233A (ja) * 2004-06-23 2008-02-07 ユーエスブイ・リミテッド 胎盤および下垂体アイソフォームに由来するキメラヒト成長ホルモンおよび該キメラを得るための方法
WO2006004719A2 (en) 2004-06-25 2006-01-12 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MX2007001180A (es) * 2004-07-26 2007-04-13 Asterion Ltd Enlazantes.
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
EP1805216A2 (de) * 2004-10-18 2007-07-11 Novo Nordisk A/S Wachstumshormonkonjugate
US20080176790A1 (en) * 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
MX2007007580A (es) * 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
WO2006074279A1 (en) * 2005-01-06 2006-07-13 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090247421A1 (en) * 2005-03-23 2009-10-01 Egisto Boschetti Diverse chemical libraries bound to small particles with paramagnetic properties
US7754861B2 (en) * 2005-03-23 2010-07-13 Bio-Rad Laboratories, Inc. Method for purifying proteins
EP1869230B1 (de) * 2005-03-23 2017-08-30 Bio-Rad Laboratories, Inc. Verfahren zur reinigung von proteinen
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
EP1866427A4 (de) * 2005-03-30 2010-09-01 Novo Nordisk As Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
BRPI0609355A2 (pt) * 2005-04-13 2010-03-30 Univ Erasmus Medical Ct uso de um antagonista do hormÈnio de crescimento, e de uma somatostatina ou de um agonista da somatostatina, na preparação de uma composição para atenuar os efeitos do hormÈnio de crescimento
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
EP1888777A4 (de) * 2005-05-19 2008-11-26 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1937719A4 (de) * 2005-08-19 2010-11-24 Novo Nordisk As Glycopegylierter faktor vii und faktor viia
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007041614A2 (en) * 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007062213A2 (en) 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
CN103789389B (zh) 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20080064039A1 (en) * 2006-07-06 2008-03-13 Pienkos Philip T Dominant negative ligand drug discovery system
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (ja) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス グリセロール連結のｐｅｇ化された糖および糖ペプチド
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2102355B1 (de) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
DK2144923T3 (da) 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2195333A1 (de) * 2007-09-12 2010-06-16 Anaphore, Inc. Auf hsp70 basierende behandlung von autoimmunkrankheiten
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
WO2009062195A2 (en) * 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8445953B2 (en) * 2009-07-08 2013-05-21 Taiwan Semiconductor Manufacturing Company, Ltd. Structure for flash memory cells
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
EP2332929A1 (de) 2009-11-25 2011-06-15 ArisGen SA Orthoester-Derivate aus Kronenäthern als Träger für diagnostische und pharmazeutische Zusammensetzungen
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
ES2582459T3 (es) 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
CA2798079A1 (en) 2010-04-28 2011-11-10 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
EP2595661A1 (de) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Wachstumshormonkonjugate
EP2446898A1 (de) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP2526971A1 (de) 2011-05-25 2012-11-28 ArisGen SA Mukosale Freisetzung von Arzneimitteln
WO2013113074A1 (en) 2012-02-03 2013-08-08 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
EP2970506A1 (de) * 2013-03-11 2016-01-20 Novo Nordisk Health Care AG Wachstumshormonverbindungen
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN104693433B (zh) * 2015-02-04 2017-06-06 国家纳米科学中心 一种聚乙二醇化氨磷汀、制备方法及其用途
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
EP3303380B1 (de) 2015-06-02 2020-01-15 Novo Nordisk A/S Insuline mit polaren rekombinanten erweiterungen
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
GB201520021D0 (en) 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
WO2019125002A1 (ko) * 2017-12-20 2019-06-27 (주)알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
WO2019211842A1 (en) * 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same
WO2020257243A1 (en) * 2019-06-17 2020-12-24 Molecular Technologies Laboratories Llc Therapeutic pegylated growth hormone antagonists
PE20230414A1 (es) 2020-03-24 2023-03-07 Genentech Inc Agentes de fijacion a tie2 y metodos de uso
WO2024026224A1 (en) 2022-07-29 2024-02-01 University Of Rochester Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853833A (en) * 1971-04-27 1974-12-10 Hormone Res Foundation Synthetic human growth-promoting and lactogenic hormones and method of producing same
US3853832A (en) * 1971-04-27 1974-12-10 Harmone Res Foundation Synthetic human pituitary growth hormone and method of producing it
US4880910A (en) * 1981-09-18 1989-11-14 Genentech, Inc. Terminal methionyl bovine growth hormone and its use
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4665160A (en) * 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (en) * 1983-07-15 1992-01-15 Bio- Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
JPH01502640A (ja) * 1987-03-12 1989-09-14 アムジエン・インコーポレーテツド ウシ成長ホルモン類似体
EP0308499B1 (de) * 1987-04-02 1993-01-07 Genencor International, Inc. Substratunterstützte katalyse
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (de) * 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
DE68929151T2 (de) * 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
EP0441889A1 (de) * 1988-11-07 1991-08-21 Commission des Communautés Européennes Modifiziertes menschliches wachstumshormon
EP0456642A1 (de) * 1989-01-31 1991-11-21 The Upjohn Company Somatotropin-analoge
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
CA2102129C (en) * 1991-05-01 2003-04-01 John J. Kopchick Growth hormone antagonists
EP0586549B1 (de) * 1991-05-10 2000-09-20 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
AU7877194A (en) * 1993-09-22 1995-04-10 American Cyanamid Company Porcine somatotropin having enhanced stability; process for producing
WO1996040203A1 (en) * 1995-06-07 1996-12-19 Ohio University/Edison Biotechnology Institute Methods of treatment using growth hormone antagonists
WO1996040731A1 (en) * 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9711178A1 *

Also Published As

Publication number Publication date
JP3628333B2 (ja) 2005-03-09
ATE455171T1 (de) 2010-01-15
EP1568772B1 (de) 2010-01-13
DE69635026T2 (de) 2006-05-24
DE69638117D1 (de) 2010-03-04
US6136563A (en) 2000-10-24
CA2658039A1 (en) 1997-03-27
LU91204I2 (fr) 2006-02-06
CA2230492A1 (en) 1997-03-27
JP3693668B2 (ja) 2005-09-07
US6004931A (en) 1999-12-21
EP0851925B1 (de) 2005-08-03
DE69635026D1 (de) 2005-09-08
WO1997011178A1 (en) 1997-03-27
ATE301196T1 (de) 2005-08-15
NL300210I2 (nl) 2007-05-01
NL300210I1 (nl) 2006-02-01
DE851925T1 (de) 2003-08-14
JPH11512298A (ja) 1999-10-26
DK1568772T3 (da) 2010-10-18
US6057292A (en) 2000-05-02
CA2230492C (en) 2009-05-26
AU7073396A (en) 1997-04-09
DE122006000003I2 (de) 2011-01-13
AU718439B2 (en) 2000-04-13
JP2005021157A (ja) 2005-01-27
EP1568771A2 (de) 2005-08-31
EP1568772A3 (de) 2006-05-17
ES2190388T1 (es) 2003-08-01
HK1012508A1 (en) 1999-08-06
ES2338431T3 (es) 2010-05-07
DK0851925T3 (da) 2005-11-28
EP1568772A2 (de) 2005-08-31
DE122006000003I1 (de) 2006-05-04
ES2190388T3 (es) 2006-04-01
US5849535A (en) 1998-12-15
PT1568772E (pt) 2010-04-14
EP1568771A3 (de) 2006-05-17

Similar Documents

Publication Publication Date Title
US6136563A (en) Human growth hormone variants comprising amino acid substitutions
US5854026A (en) Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1
JP2957974B2 (ja) エリスロポエチン活性を有するタンパク質の製造方法
JP2996415B2 (ja) 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
US20020009798A1 (en) Ob protein compositions and methods
BG60256B2 (bg) Рекомбинантен метод за получаване на лимфотоксин
SK279897B6 (sk) Spôsob izolácie ľudského nekrotizujúceho faktora (
EP0403601B1 (de) Somatropine
US5130422A (en) Variant somatotropin-encoding DNA
KR100272867B1 (ko) Tpo활성을 갖는 단백질
EP0410751B1 (de) Für M-CSF kodierendes Gen und dazu gehörende rekombinante Systeme
AU723413B2 (en) An interleukin-5 antagonist
AU4866700A (en) OB protein compositions and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRCL

TCAT At: translation of patent claims filed
EL Fr: translation of claims filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: PP

Ref document number: 20030300007

Country of ref document: GR

DET De: translation of patent claims
17Q First examination report despatched

Effective date: 20031010

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENTECH, INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69635026

Country of ref document: DE

Date of ref document: 20050908

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1012508

Country of ref document: HK

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051103

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: SPC/GB05/047: 20051026

Spc suppl protection certif: SPC/GB05/047

Filing date: 20051026

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050403016

Country of ref document: GR

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: L20050027

REG Reference to a national code

Ref country code: FR

Ref legal event code: MS

Free format text: MS FOR DOCUMENT: FR05C0043

Ref country code: FR

Ref legal event code: CR

Free format text: PRODUCT NAME: PEGVISOMANT LE CAS ECHEANT SOUS FORME D UN VARIANT DE PEGYLATION; REGISTRATION NO/DATE IN FRANCE: EU/1/02/240/001 DU 20021113; REGISTRATION NO/DATE AT EEC: EU/1/02/240/001-003 DU 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051103

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

REG Reference to a national code

Ref country code: DE

Ref legal event code: V448

Free format text: PRODUCT NAME: SOMAVERT-PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - EU/1/02/240/003; 20021113

Spc suppl protection certif: 12 2006 000 003

Filing date: 20060125

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: PEGVISOMANT, ELLER VALFRITT I FORM AV EN VARIANT AV PEGVISOMANT; NAT REG. NO/DATE: EG EU/1/02/240/001-003 20021113; FIRST REG.: EG EU/1/02/240/001-003 20021113

Spc suppl protection certif: 06900021.L

Ref country code: SE

Ref legal event code: SPCF

Free format text: 0690002-1, 20021113

Spc suppl protection certif: 0690002-1

Filing date: 20021113

REG Reference to a national code

Ref country code: NL

Ref legal event code: AC1

Spc suppl protection certif: 300210

Filing date: 20051130

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCF

Ref document number: 502005901355991

Country of ref document: IT

Free format text: AUTHORISATION NUMBER(S) AND DATE(S): EU/1/02/240/001-003, 20021113

Spc suppl protection certif: 132006901381900

REG Reference to a national code

Ref country code: LU

Ref legal event code: CCP

Free format text: 91204, EXPIRES: 20171113

Spc suppl protection certif: 91204

Expiry date: 20171113

RIN2 Information on inventor provided after grant (corrected)

Inventor name: FUH, GERMAINE G.

Inventor name: OLSON, KENNETH

Inventor name: CLARK, ROSS G.

Inventor name: WELLS, JAMES A.

Inventor name: LOWMAN, HENRY B.

Inventor name: CUNNINGHAM, BRIAN C.

REG Reference to a national code

Ref country code: AT

Ref legal event code: ESZA

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: PEGVISOMANT

Spc suppl protection certif: SZ 43/2005

Filing date: 20051221

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2190388

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57144 11.10.2005

Spc suppl protection certif: C00851925/01

Filing date: 20060403

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCG

Ref document number: 502005901355991

Country of ref document: IT

Free format text: AUTHORISATION NUMBER(S) AND DATE(S): EU/1/02/240/001-003, 20021113

Spc suppl protection certif: 132006901381900

Extension date: 20171112

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060504

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8364

Ref document number: 69635026

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: SPC/GB05/047: 20060831, EXPIRES: 20171112

Spc suppl protection certif: SPC/GB05/047

Filing date: 20060831

Expiry date: 20171112

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCG

Free format text: SPC029/2005: 20061023, EXPIRES: 20171112

Spc suppl protection certif: SPC029/2005

Filing date: 20061023

Expiry date: 20171112

REG Reference to a national code

Ref country code: NL

Ref legal event code: KC1

Free format text: 300210, 20160920, EXPIRES: 20171112

Spc suppl protection certif: 300210

Filing date: 20051130

Expiry date: 20171112

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEZF

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: PEGVISOMANT

Spc suppl protection certif: SZ 43/2005

Filing date: 20051221

Extension date: 20171113

Effective date: 20070406

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Spc suppl protection certif: CA 2005 00043

Filing date: 20051117

Expiry date: 20171113

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57144 11.10.2005

Spc suppl protection certif: C00851925/01

Filing date: 20060403

Extension date: 20201010

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Spc suppl protection certif: 06900021.L

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0690002-1

Spc suppl protection certif: 0690002-1

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFG

Free format text: PRODUCT NAME: PEGVISOMANT

Spc suppl protection certif: CA 2005 00043

Filing date: 20051117

REG Reference to a national code

Ref country code: FR

Ref legal event code: CT

Free format text: PRODUCT NAME: PEGVISONMANT, LE CAS ECHEANT SOUS FORME D'UN VARIANT DE PEGYLATION; REG. NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051103

Extension date: 20171113

Ref country code: FR

Ref legal event code: AV

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCG

Spc suppl protection certif: 268

Extension date: 20171113

REG Reference to a national code

Ref country code: DE

Ref legal event code: V484

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - EU/1/02/240/003; 20021113

Spc suppl protection certif: 12 2006 000 003

Filing date: 20060125

REG Reference to a national code

Ref country code: DE

Ref legal event code: V457

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - EU/1/02/240/003; 20021113

Spc suppl protection certif: 12 2006 000 003

Filing date: 20060125

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCN

Free format text: FORMER REPRESENTATIVE: BOVARD AG PATENTANWAELTE, CH

Spc suppl protection certif: C00851925/01

Representative=s name: BOVARD SA, CH

Ref country code: CH

Ref legal event code: PFA

Owner name: GENENTECH, INC.

Free format text: GENENTECH, INC.#1 DNA WAY#SOUTH SAN FRANCISCO, CA 94080-4990 (US) -TRANSFER TO- GENENTECH, INC.#1 DNA WAY#SOUTH SAN FRANCISCO, CA 94080-4990 (US)

REG Reference to a national code

Ref country code: FR

Ref legal event code: SPCM

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051209

REG Reference to a national code

Ref country code: FR

Ref legal event code: SN

Effective date: 20130619

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCX

Free format text: PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113

Spc suppl protection certif: SPC/GB05/047

Filing date: 20051016

Extension date: 20171114

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150624

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150825

Year of fee payment: 20

Ref country code: IE

Payment date: 20150826

Year of fee payment: 20

Ref country code: CH

Payment date: 20150724

Year of fee payment: 20

Ref country code: DK

Payment date: 20150826

Year of fee payment: 20

Ref country code: FI

Payment date: 20150907

Year of fee payment: 20

Ref country code: ES

Payment date: 20150915

Year of fee payment: 20

Ref country code: PT

Payment date: 20150827

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20150828

Year of fee payment: 20

Ref country code: AT

Payment date: 20150825

Year of fee payment: 20

Ref country code: SE

Payment date: 20150908

Year of fee payment: 20

Ref country code: BE

Payment date: 20150916

Year of fee payment: 20

Ref country code: LU

Payment date: 20151007

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20150914

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150930

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150930

Year of fee payment: 20

REG Reference to a national code

Ref country code: FR

Ref legal event code: SPAY

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051103

Year of fee payment: 1

Extension date: 20171113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69635026

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20160919

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20160920

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160919

Ref country code: GB

Ref legal event code: CTFE

Free format text: PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTERED: UK EU/1/02/240/001 20021115; UK EU/1/02/240/002 20021115; UK EU/1/02/240/003 20021115

Spc suppl protection certif: SPC/GB05/047

Filing date: 20051026

Expiry date: 20160920

Extension date: 20171114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R456

Ref document number: 69635026

Country of ref document: DE

Free format text: PRODUCT NAME: WIRKSTOFFZUSAMMENSETZUNG UMFASSEND PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 122006000003

Filing date: 20060125

Expiry date: 20160921

Extension date: 20171115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160919

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160920

REG Reference to a national code

Ref country code: DE

Ref legal event code: R432

Ref document number: 69635026

Country of ref document: DE

Free format text: PRODUCT NAME: WIRKSTOFFZUSAMMENSETZUNG UMFASSEND PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 122006000003

Filing date: 20060125

Expiry date: 20160921

Extension date: 20171115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160928

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160920

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20050403016

Country of ref document: GR

Effective date: 20160921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160921

REG Reference to a national code

Ref country code: FR

Ref legal event code: SPAY

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 05C0043

Filing date: 20051103

Year of fee payment: 2

Extension date: 20171113

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCX

Free format text: PRODUCT NAME: PEGVISOMANT; NATIONAL REGISTRATION NO/DATE: EU/1/02/240/002 20021115; FIRST REGISTRATION: EU EU/1/02/240/001 20021115

Spc suppl protection certif: 300210

Filing date: 20051130

Expiry date: 20160919

Extension date: 20171114

Ref country code: DE

Ref legal event code: R071

Ref document number: 69635026

Country of ref document: DE

Free format text: PRODUCT NAME: WIRKSTOFFZUSAMMENSETZUNG UMFASSEND PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001-003 20021113

Spc suppl protection certif: 122006000003

Filing date: 20060125

Expiry date: 20160921

Extension date: 20171115

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCE

Free format text: PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTERED: UK EU/1/02/240/001 20021115; UK EU/1/02/240/002 20021115; UK EU/1/02/240/003 20021115

Spc suppl protection certif: SPC/GB05/047

Filing date: 20051026

Expiry date: 20160920

Extension date: 20171114

REG Reference to a national code

Ref country code: BE

Ref legal event code: SPCX

Free format text: PRODUCT NAME: PEGVISOMANT; AUTHORISATION NUMBER AND DATE: EU/1/02/240/001 20021115

Spc suppl protection certif: 2005C/037

Extension date: 20171115

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCC

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113

Spc suppl protection certif: 43/2005

Filing date: 20051221

Expiry date: 20160920

Extension date: 20171115

Effective date: 20180315

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCX

Ref document number: 301196

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: PEGVISOMANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113

Spc suppl protection certif: 43/2005

Filing date: 20051221

Expiry date: 20160920

Extension date: 20171115

Effective date: 20171115

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCL

Spc suppl protection certif: C00851925/01